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ABSTRACT OF THE DISSERTATION 
The Role of FGF Signaling in Epicardial-Derived Cardiac Fibroblast Development 
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Professor David M. Ornitz, Chairperson 
 
In this thesis I examined the function of Fibroblast Growth Factor (FGF) 
signaling in epicardial cells. Epicardial cells serve as the outer layer of the heart and 
as a signaling center for the growing myocardium. In addition, during development, 
epicardial cells differentiate into vascular smooth muscle cells (vsmc) and interstitial 
fibroblasts. Epicardial cells undergo an epicardial to mesenchymal transition (EMT) 
to give rise to these various cell types, which are termed epicardial derived cells 
(EPDCs). Epicardial-derived vsmc are an essential component of the arterial network 
in the myocardium, and the interstitial fibroblasts become part of the fibrous skeleton 
of the myocardium. To populate the myocardium, EPDCs must migrate through the 
subepicardial space and into the compact myocardium. Very little is known about 
how this migration is initiated, maintained and guided.  
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 Although, FGF7 and FGF10 are expressed in the myocardium their function 
was not known. Biochemically, these FGFs activate the b splice variants of FGFR1 
and FGFR2. Here, I show that FGF10 siganls to the epicardium in vivo to induce 
migration of EPDCs. Furthermore, I found that FGF10 promotes migration of EPDCs 
that are fated to become interstitial fibroblasts. Embryonic cardiac fibroblasts are 
important during late heart gestation because they induce proliferation of cardiac 
myocytes. In hearts in which the FGF10/FGFR2b signaling pathway is disrupted, 
cardiac fibroblasts fail to migrate into the myocardium. I posit that fewer interstitia l 
cardiac fibroblasts results in decreased cardiac myocyte proliferation and a smaller 
heart. Other growth factors like PDGFβ had been identified to activate migration of 
epicardial-derived vsmc but not cardiac fibroblast. Thus it appears that specific 
extracellular signaling pathways are required to control the migration of EPDC-
lineages into the myocardium. These findings are an important contribution to the 
understanding of epicardial development. Epicardial and EPDC are not only 
important for heart development, but are thought to be essential for heart repair and 
regeneration due to the potential of these cells to differentiate in various cell types 
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Introduction 
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Summary 
 
Epicardial Derived Cells (EPDCs) can differentiate into various cell types and 
migrate to be recruited in the periphery of endothelial vessels and as part of the fibrous 
skeleton of the heart. The ability of EPDCs to differentiate into multiple cell types suggests 
the potential implication for these cells in heart repair. Many scientists are attempting to 
learn about the developmental pathways required to activate them in the adult heart.  The 
mechanisms that regulate the differentiation and migration of EPDCs are poorly understood. 
The work in this thesis led to the discovery of a new developmental pathway that regulates 
EPDC migration and indirectly myocardial proliferation. The observation that embryos 
lacking a splice variant of FGF receptor 2 that is expressed in the epicardium have small 
hearts suggested that a signal to the epicardium is required to control heart size.  This 
phenotype prompted us to look closely at the development of the epicardium. To investigate 
the underlying mechanisms we studied heart development in embryos lacking epicardial 
FGF receptors and FGF ligands that could signal to these receptors. Our findings suggests 
that that growth of the myocardium is directly linked to decreased numbers of EPDCs.  In 
addition these studies identify a signaling pathway that specifically regulates migration of 
epicardial-derived cardiac fibroblasts and supports a hypothesis that EPDC lineages within 
the myocardium are independently regulated by distinct growth factor signaling pathways. 
These findings are an important contribution to the understanding of heart development 
because it provides a basis to support the hypothesis that smooth muscle cell and cardiac 
fibroblast require the induction of independent signals to migrate into the myocardium.  
Elucidating which other signals promote the migration of smooth muscle cells versus 
cardiac fibroblast could lead to a comprehensive understanding of epicardial cell activation. 
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This understanding is necessary to further design functional experiments to manipulate 
epicardial cells for heart repair. Below I summarize the literature on epicardial origins, 
development, differentiation, migration and function within the heart. In addition, I examine 
mechanisms of FGF signaling, heart development, the known functions of FGF in heart 
development and finally focus specifically on discussing the developmental process 
regulating the formation of the epicardium and epicardial derived cells.  
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Overview of the Fibroblast Growth Factor Family  
The mouse family of Fibroblast Growth Factors (FGFs) is large and diverse. It is 
comprised of the intracellular FGFs (iFGFs), the canonical FGFs and the hormone-like 
FGFs (hFGF) (Itoh and Ornitz, 2008). The members of the iFGF family are: Fgf11, Fgf12, 
Fgf13 and Fgf14 (Smallwood et al., 1996). Intracellular FGFs are similar in sequence and 
structure to canonical and hormone-like FGFs but differ in function (Olsen et al., 2003). 
iFGFs exert their function inside the cell where they are known to bind to sodium channels 
and modulate neuron excitability (Laezza et al., 2007; Laezza et al., 2009; Lou et al., 2005; 
Xiao et al., 2007). It has been proposed that an iFGF-like protein was the common ancestor 
to all known FGFs. Unlike the intracellular FGFs, which do not bind to FGF receptors, the 
canonical and hormone-like FGFs are secreted outside the cells (Hanneken et al., 1994). 
These are able to signal by the binding of receptor tyrosine kinases from the FGF family of 
receptors (Rudland et al., 1974). The subfamily of hFGF is comprised of Fgf15 (being 
Fgf19 its ortholog in humans), Fgf21 and Fgf23 (Kharitonenkov et al., 2005). 
 Hormone-like FGFs are thought to arise in a recent event of vertebrate evolution; as 
a result they lost their high affinity for binding heparin and acquired their endocrine 
characteristics. A unique feature of hFGFs is the necessity of the cofactors αKlotho and 
βKloto to enhance signaling through FGF receptors (FGFR) (Kurosu and Kuro, 2009).  In 
contrast, canonical FGFs signal in an autocrine/paracrine fashion due to their high affinity 
for heparan sulfate (Ornitz and Leder, 1992).  
Canonical FGFs can be divided in the following subgroups based on sequence 
similarity: FGF1 subfamily (comprised of: Fgf1, Fgf2), FGF4 subfamily (comprised of: 
Fgf4, Fgf6 and Fgf5), FGF7 subfamily (comprised of: Fgf3, Fgf7, Fgf10 and Fgf22) and 
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FGF8 subfamily (comprised of: Fgf8, Fgf17) (Ornitz, 2003). Canonical FGFs signal through 
FGF receptor tyrosine kinases (which are: Fgfr1, Fgfr2, Fgfr3 and Fgfr4) (Coutts and 
Gallagher, 1995). FGF receptors have a unique structure composed of three main parts: the 
extracellular region with three characteristic immunoglobulin-like domains, a single 
transmembrane domain, and a cytoplasmic domain containing the tyrosine kinase activity 
(Baird et al., 1988). The mRNA of the receptors bears an alternative splicing site that 
produces the “c-splice variants” and the “b-splice variant” of receptors Fgfr1, Fgfr2 and 
Fgfr3 but not of Fgfr4 (Fujita et al., 1991).  
It has been consistently observed that the c-splice variant is preferentially expressed 
in mesenchymal-like tissues and the b-splice variant is preferentially expressed in epithelial-
like tissues. The ability of the receptors to undergo alternative splicing confers tissue and 
ligand binding specificity to the signal, making it ideal to control interactions between 
epithelia and mesenchyme during development (Yeh et al., 2003). To complement the 
specific pattern of expression of the receptor splice variants, the FGF ligands found within 
subgroups have higher affinity for specific receptors splice variants (Ornitz et al., 1996).  
For example, the members of the Fgf7 family bind FGFR2b with high affinity but do not 
bind FGFR2c. Ligands within a subfamily and corresponding receptors of the same splice 
variantare typically found to be expressed simultaneously in adjacent tissues. Ontogeny 
requires a precise and fine-tuned network of signals to orchestrate the formation of a default 
outcome; therefore, continued monitoring of signal transduction is necessary to achieve the 
default state. The complementary expression of FGF ligands and receptors in epithelial and 
mesenchymal tissues allow the formation of signaling feedback loops that provide a way to 
monitor the timing, frequency and strength of FGF developmental interaction, ensuring 
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proper regulation of tissue development and morphogenesis (Niswander et al., 1994; Zhang 
et al., 2006).  
The ligand binding domain is located at the second and third immunoglobulin 
domain of the FGF receptors (Mohammadi et al., 2005). Although the mechanism is still 
under investigation, one accepted mechanism of ligand binding is referred to as the “Ligand 
Dimer“. In this mechanism, activation of the receptor occurs when one FGF ligand binds to 
the cell surface heparin sulphate proteoglycan (HSPG) chain and simultaneously induces 
receptor dimerization (Ornitz et al., 1995). Receptor dimerization causes a conformational 
change at the intracellular domain that activates the phosphotyrosine kinase and leads to 
trans-autophosphorilation of the cytoplasmic tails as they come closer to each other (Bae et 
al., 2010). Activation of the phosphotyrosine binding domain (PTB) in FGFR 
phosphorylates the scaffolding protein FRS2; this leads to the recruitment of other proteins 
that will activate downstream effector pathways (Zhang et al., 2008). Recruitment of SOS 
and GRB2 leads to activation of the downstream pathway RAS/MAPK (Kouhara et al., 
1997). On the other hand, recruitment of GAB1 leads to the activation of downstream 
pathway PI3K/AKT (Ong et al., 2001). A different activation mechanism distinct from 
FRS2 is the recruitment of PLCγ to a different phosphotyrosine residue  within the FGFR 
cytoplasmic tail which leads to activation of PKC and strengthens the MAPK pathway 
transduction by phosphorylating RAS (Mohammadi et al., 1991).  
Regulation and modification of the FGF signal can occur at various levels of the 
signaling pathway to render context-dependent signaling. First, the restricted pattern of 
expression of the ligands, as well as the receptors, limits possible promiscuous interactions. 
Second, the alternative splicing of the receptors results in selective affinity of ligand-
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receptor binding. Third, the interaction of the heparan sulfate proteoglycan with the receptor 
and ligand can modulate strength and specificity of signal as well as cell type-specific 
interaction due to the diverse spatial and temporal expression of the many types of HSPG. 
Finally, the Sprouty proteins can modulate FGF signaling by suppressing the MAPK 
transduction pathways in a feedback loop dependent manner (Lo et al., 2006). The FGF 
signal is interpreted based on the spatial-temporal and cellular context of the cell activated 
(Sivak et al., 2005). The activation of FGF signaling could cause changes in proliferation, 
differentiation, migration and survival.  In this thesis, I investigate functions of FGF10, 
FGFR2b and FGFR1b in epicardial cells, the outermost layer of the heart.  
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Overview of Heart Development  
The heart is the first organ to develop in the mammal and is required to provide 
oxygen and nutrient exchange to the growing embryo (Rudolph, 2010). Much research has 
focused on studying the origins of the cells that make up the heart. Un-committed precursor 
cells of the heart have been mapped to the primitive streak (Garcia-Martinez and 
Schoenwolf, 1993). Gastrulation at the primitive streak leads to the migration of the pre-
cardiac mesoderm to the anterior side of the embryo (Christiaen et al., 2010). The cardiac 
mesoderm organizes into two groups of cells in each side of the midline (Nakajima et al., 
2009).  These cells form the primary heart field (PHF) that later comes together at the 
midline to form the primary tubular heart (Ramsdell and Yost, 1999).  
A secondary heart field originally located below the PHF contributes more cells to 
the arterial and venous poles of the tubular heart (Moorman et al., 2007; Vincent and 
Buckingham, 2010). The tubular heart loops to the right, leading its posterior region to the 
anterior side of the embryo. Looping combined with myocardial expansion leads to the 
shaping of the cardiac chambers (Taber et al., 2010). Soon after heart looping, another cell 
population originates at the sinuous venosus — the proepicardium — and travels to the heart 
to form the epicardial layer (Dettman et al., 1998). Another sprouting of cells from the 
sinous venosus but distinct from the proepicardium differentiates to the endothelial cells of 
the coronary vessels (Red-Horse et al., 2010).  As development continues, endocardial cells 
lining the heart lumen undergo epithelial to mesenchymal transition (EMT) to give rise to 
the cardiac jelly and cardiac cushions (Person et al., 2005).  Rapid growth of the 
myocardium aids with the formation of the chamber septa, these are the interventricular and 
atrial septae. Another population of cells from the neural crest travels though the pharyngeal 
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arches into the outflow tract (OFT). These cells contribute to form the septation in the 
pulmonary trunk and aorta. These cells also contribute to form the electrical network of the 
heart (Brown and Baldwin, 2006).  
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FGF Function in Heart Development  
FGF signaling is important during different events in heart development. Initially, 
expression of FGF ligands and FGF receptors was observed within the developing heart, 
suggesting a putative role for these molecules (Zhu and Lough, 1996). Early on it was 
shown that FGF2 was expressed in stage six of the chicken embryo and that Fgf2 antisense 
oligonucleotides could inhibit proliferation of cultured pre-cardiac anterior avian mesoderm 
(Sugi et al., 1993). Proliferation of pre-cardiac mesoderm is known to be important in the 
generation of the tubular heart. Likewise expression of FGF1 and FGF4 were reported in the 
chicken myocardium from stages eleven to twenty four (Zhu et al., 1996). Expression of 
Fgf7 was also reported in cardiomyocytes as early as embryonic day 10.5 (E10.5) but to 
date no functional in vivo evidence has been examined to attribute a role of FGF7 in heart 
development (Mason et al., 1994).  
The first in vivo evidence of FGF signaling controlling myocyte proliferation came 
from a study in chicken where an Fgfr1 dominant negative retroviral vector introduced 
during the first week of chicken development was able to decrease myocardial proliferation 
(Mima et al., 1995). FGF signaling was further implicated in heart development when a null 
mutant embryo of Heartless, a Drosophila FGF receptor homolog was found unable to 
induce the pre-cardiac mesoderm and yielded a heartless fly (Beiman et al., 1996). 
Similarly, in vertebrates, Fgf8 was found to be expressed in the cardiac endoderm that lays 
contiguous with the cardiac-mesoderm. Physical removal of this endoderm caused 
downregulation of cardiac markers; complementary to this observation, external addition of 
FGF8 could restore the expression of these markers (Alsan BH, 2002). After the discovery 
of the secondary heart field in 2001 it was shown that expression of an Fgf10 enhancer trap 
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bearing β-galactosidase mapped myocytes derived from the secondary heart field in the OFT 
and right ventricle (Waldo et al., 2001). This observation suggested that FGF10 expressing 
cells were exclusively part of the secondary heart field lineage proposed to be of 
independent origin from the PHF (Kelly et al., 2001). Although these studies implicated a 
role for FGF8 and FGF10 in development and expansion of the cardiac fields, Fgf8 null 
mutants only displayed disruption in OFT and right ventricle formation but no major defect 
in heart development and Fgf10
-/-
 only showed a defect in abnormal positioning of the 
ventricular apex. Recent studies conditionally knocking both Fgf8 and Fgf10 from the 
mesoderm confirmed that these ligands have overlapping functions at the secondary heart 
field and gene dosage is important for the penetrance of OFT defect and pharyngeal arch 
artery formation (Watanabe et al., 2010). Specific SHF deletion of Fgf8 and FGF receptors 
have also been generated to conclude that FGF signaling in the SHF acts in an autocrine 
manner.  
Similarly to its functional effects in early heart development, FGF signaling 
functions in other stages of heart development. For example, it has been found that Fgf4 
expressed in cardiac cushion mesenchyme can cause proliferation of these cells. 
Microinjection of Fgf4 protein in vivo to chicken embryos resulted in increased proliferation 
of cushion mesenchyme, providing evidence of functional requirement of Fgf4 during this 
process (Sugi et al., 2003). Heart growth can happen by proliferation of cardiac myocytes 
and other cell types within the heart or by cellular hypertrophy. Proliferation of 
cardiomyocytes is the preferred mechanism of heart growth during heart development. It has 
been postulated that two significant myocardial expansions happen after heart looping. One 
happens immediately after looping and another one during late gestation (Lavine and Ornitz, 
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2008).  The midgestational bout of myocardial proliferation happens simultaneously with 
the formation of the epicardial layer (Lavine and Ornitz, 2008). This coincident 
development has been proposed to be part of the mechanism of myocardial proliferation 
during midgestation. The epicardium is considered a center of proliferative signals for the 
myocardium (Sucov et al., 2009). 
 The first observation pointing to such a mechanism came from studies of the retinoic 
acid receptor alpha (RXRα). Deletion of this receptor resulted in hypoplastic ventricles. 
RXRα was shown to function in the epicardium and proposed to regulate secretion of 
growth factors from the epicardium that in turn could stimulate myocardial proliferation 
(Chen et al., 2002). These growth factors were later determined to be FGF9 and FGF16. 
Studies characterizing the Fgf9
-/- 
embryos
 
revealed these embryos had a small heart due to a 
decrease in myocardial proliferation. Complementary deletion of both Fgfr1 and Fgfr2 
specifically in the myocardium recapitulated the phenotype observed in Fgf9
-/-
hearts. 
Moreover, FGF9 and FGF16 were found to be expressed in the epicardium and 
endocardium, leading to the hypothesis that FGF signaling contributions from epicardium 
and endocardium regulate cardiac growth during midgestation (Lavine et al., 2005). 
Consistent with these findings Fgf16
-/-
 hearts also display decreased embryonic proliferation 
consistent with a synergistic role with FGF9 during heart development (Hotta et al., 2008). 
Another important role of FGF signaling during midgestation is that it regulates the timing 
of formation of the primitive vascular plexus by indirectly activating SHH signaling. It is 
still unknown how FGF  regulates SHH in the epicardium (Lavine et al., 2006).  
FGF signaling is also important during homeostasis and maintenance of the adult 
heart. The earliest observation of FGF function in the adult heart came from studies of gene 
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expression. For example, expression of different FGF ligands in cardiomyocytes was 
observed after induced cardiac stenosis (Bernotat-Danielowski et al., 1993). These data 
suggested that FGF signaling was required during heart homeostasis. More recently , FGF2 
has become the center of much research since it has been found to have cardioprotective 
capabilities (Kardami et al., 2007). The cardioprotectiveness by FGF2 was first observed in 
isolated models of ischemia-reperfusion. In this study, administration of FGF2 after 
ischemia lead to improvements in mechanical function (Padua et al., 1995). Consistent with 
the observed protective role of FGF2 during heart ischemia, transgenic hearts 
overexpressing Fgf2 displayed higher myocyte viability (Sheikh et al., 2001).  
Overexpression of FGF2 was also protective in cardiac infarct models (House et al., 
2003; House et al., 2005; House et al., 2007). Administration of FGF2 to myocardial 
infarcted hearts resulted in a decrease of ischemia activated cell dead and arrhythmias. 
FGF2 can be translated in two different isoforms; one is low molecular weight FGF2 (lo-
FGF2), and the other is high molecular weight FGF2 (hi-FGF2) (Liao et al., 2009). The 
specific role of each isoform in cardioprotection is unclear (Liao et al., 2007). Currently, 
knockouts for both isoforms have been generated for cardioprotection. Both isoforms have 
similar effects immediately after acute ischemia. The main difference found was that hi -
FGF2 had a stronger induction of PKCδ and p70 S6 kinases (Jiang et al., 2009). Another 
possible FGF involved in adult heart homeostasis is FGF16. Interest in FGF16 has increased 
due to its expression peak in the perinatal heart. Particularly intriguing is the existence of an 
NF-κB element in FGF16’s promoter sequence. The NF-κB site has been found to be 
responsive to NF-κB induction by isoproterenol, suggesting that it could be activated upon 
NF-κB binding (Sofronescu et al., 2010).  
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Overview of Epicardial Development  
 Epicardial development initiates with the formation of the proepicardium (Figure 1). 
Development of the proepicardium has been studied in: Xenopus laevis, zebrafish, 
Acipenser naccari and mammals, suggesting that it is an evolutionarily conserved biological 
process. (Icardo et al., 2009; Jahr et al., 2008; Serluca, 2008). The proepicardium is a 
cauliflower-like bundle of cells located anterior to the inflow of the heart (Nesbitt et al., 
2006). Proepicardial cells travel to the atrioventricular grove of the heart. Further migration 
over the myocardial surface results in the formation of the epicardial mantle (Mikawa and 
Gourdie, 1996). These now-termed epicardial cells undergo an epithelial to mesenchymal 
transition to invade the myocardium where they differentiate into cardiac fibroblast and 
vascular smooth muscle cells.  
Proepicardial and epicardial cells have the potential to differentiate into various cell 
types, making them plausible candidates to elicit repair in the adult heart (Winter and 
Gittenberger-de Groot, 2007). Studies have tried to trace the lineage of the proepicardial 
cells. Using Cre-loxP lineage tracing it was observed that proepicardial cells are derived 
from Nkx2-5 and Isl1 progenitors (Zhou et al., 2008b). Consistent with this observation, 
Nkx2-5 null mutants fail to form a proepicardial structure, in contrast, the proepicardium 
forms in the Isl1 knockout mice. Similar to Nkx2-5
-/-
 the Gata4
-/- 
do not form a proepicardial 
organ, as a result the heart does not develop an epicardial layer (Watt et al., 2004). These 
studies give insight into the lineage origin of proepicadial cells, but do not elucidate how 
proepicardial cells are specified to the proepicardial fate from myocardial precursors (van 
Wijk and van den Hoff, 2010). Recent studies in chicken indicated that a balance between 
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BMP2 and FGF2 signaling is responsible for the early separation between myocardial 
progenitors and proepicardial progenitors (van Wijk et al., 2009). BMP is responsible for 
driving myocardial cell fate and FGF is responsible for driving proepicardial cell fate.  
Once proepicardial cells are specified, they express markers for Wt1, TBX18, TCF21 
and capsulin, amongst others (Hatcher et al., 2000; Lu et al., 1998; Moore et al., 1999; Robb 
et al., 1998). Expression of these markers was used as a symbol of lineage commitment in 
zebrafish studies. These studies suggested that TBX5a and BMP4 are important for 
proepicardial commitment (Hatcher et al., 2004). Mutant fish of either tbx5a or acvr1l (the 
receptor for BMP4) repressed expression of proepicardial markers TCF21 and TBX18. 
Normal expression of BMP4 in tbx5a mutants lead to the hypothesis that TBX5a promotes 
competency of the lateral plate mesoderm to commit to the proepicardial cell fate. 
Complementary BMP4 signaling was responsible for guaranteeing their commitment later 
on (Liu and Stainier, 2010).  
Proepicardial development has been studied in chickens and in mice, therefore, it is 
important to mention key differences between proepicardial and epicardial development 
between these species. In the chicken, the proepicardium develops from bilaterally 
symmetrical buds of proepicardial cells that form a final asymmetrical structure on the right 
side of the embryo (Nahirney et al., 2003). In the mouse, both proepicardial buds develop 
uniformly and symmetrically (Schulte et al., 2007). FGF8 and Snail1 were found to control 
the left-right (L-R) asymmetry of the chicken proepicardium. Inhibition of snail in the right 
side prevented proepicardial formation. Overexposure of FGFR1 and FGF8 on the left side 
of the proepicardial field was sufficient to drive ectopic proepicardial formation (Schlueter 
and Brand, 2009).  Proepicardial asymmetry is lost in the mouse, but it would be interesting 
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to investigate if manipulation of these signals could generate an asymmetric proepicardium 
in the mouse. 
 Once the proepicardium has been specified and formed, proepicardial cells have 
been reported to express markers of different cell fates.  Although it is not proven yet, this 
observation has promoted the idea that cells within the proepicardium are already specified 
to become cardiac fibroblast or smooth muscle cells prior to their migration to the 
epicardium. Another possibility is that EPDCs differentiate as they migrate into the 
myocardium. More research in this area of epicardial development is needed to discern 
which of these two possibilities is correct. 
 Migration of proepicardial cells to the atrioventricular grove has been studied in 
chickens and mice using SEM and histological analysis. In chickens, proepicardial cells 
start migrating at stage HH14 and form an extracellular matrix bridge made of 
proteoglycans, heparin sulfate and fibronectin that guides the proepicardial cells into the 
heart (Nahirney et al., 2003). Migration of proepicardial cells in mouse starts at E9. In areas 
of the proepicardium that are closest to the bare myocardium, cells start to swell and form 
multicellular villous clusters that extend towards the heart. Once these clusters have 
achieved sufficient length to contact the heart, the tip of the cluster touches the nude 
myocardium. Beating pulls the tip off the cluster leaving the epicardial cells attached to the 
myocardium. Villous tips detach and float to reach the myocardium at areas where its 
unable to touch and attach to the nude myocardium (Rodgers et al., 2007).  
Very little is known about the molecules directing the migration of proepicardial 
cells towards the myocardium. Evidence that adhesion is important for proepicardial 
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migration can be found in the phenotype of the integrin α4β1 knockout mouse.  α4β1 is a 
cell adhesion molecule.  α4β1 null mice display defects in villous budding (Sengbusch et al., 
2002). VCAM1, the ligand for α4β1, can recapitulate the defects seen in the receptor null 
embryos (Pae et al., 2008). Another molecule that presents a similar phenotype when 
inactivated is RXRα. This nuclear receptor has been found to have a role during 
proepicardial migration. Proepicardial cells of Rxrα−/− hearts have a higher rate of apoptosis 
compared to controls and display a decreased number of villous clusters contacting the 
myocardium. Furthermore, formation of the epicardial layer is disrupted due to detachments 
of epicardial cells and incomplete coverage of the myocardium. These defects could be 
attributed to a decreased number of epicardial cells migrating to envelop the heart (Jenkins 
et al., 2005). Deletion of the glycoprotein Podoplanin results in a smaller proepicardial 
organ, which impairs migration of proepicardial cells, upregulates ecadherin at the 
epicardium and results in decreased amounts of Epicardial Derived Cells within the 
myocardium (Mahtab et al., 2009).  Also, both overexpression and repression of TBX5 in 
chicken leads to inhibition of proepicardial migration to cover the myocardium (Hatcher et 
al., 2004).  
After proepicardial cells have migrated, they need to cover the heart and attach their 
basement membrane to the myocardium. It is hypothesized that adhesion molecules are 
important to mediate attachment of the epicardial layer to the myocardium. Interestingly, in 
addition to problems of proepicardial migration disruption of α4β1, VCAM1, rxrα, 
podoplanin and tbx5 function also results in problems adhering to the nude myocardium. 
Typically, a characteristic phenotype of epicardial detachment is the formation of epicardial 
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sacs that lack direct contact between the epicardium and the myocardium (Jenkins et al., 
2005; Pae et al., 2008; Sengbusch et al., 2002). 
After the epicardium has covered the heart and properly adhered to the myocardium, 
a subset of epicardial cells undergo epicardial to mesenchymal transitions. Epicardial cells 
become mesenchymal and delaminate into the subepicardial mesenchyme (Gittenberger-de 
Groot et al., 2010; Perez-Pomares et al., 1998). Once in the subepicardial mesenchyme, 
epicardial derived cells migrate further into the myocardium. These cells are named EPDCs.  
The observation that epicardial mesenchyme gives rise to a large part of the adult 
heart was made during the 1990s by several different laboratories using clonal retrovirals to 
trace the lineage of these cells (Dettman et al., 1998; Mikawa and Gourdie, 1996; Perez-
Pomares et al., 1997). EPDCs differentiate into vascular smooth muscles cells and pericytes 
which outline the endothelial vascular plexus. They also give rise to interstitial fibroblasts, a 
cell type that has been shown to control myocyte proliferation (Weeke-Klimp et al., 2010). 
Therefore, failure to properly adhere to the myocardium, undergo EMT, migrate into the 
myocardium and differentiate could result in cardiac heart defects. Researchers in the field 
are trying to elucidate how epicardial cells become activated and competent to undergo 
EMT. Canonical EMT occurs by the dissolution of cell-cell junctions, loss of apical-basal 
polarity, and finally the modification of cytoskeletal proteins to a mesenchymal phenotype 
that permits  — in the case of epicardial cells — to coalesce within the subepicardial space 
(Thiery et al., 2009).  
It is not known yet if epicardial EMT happens throughout canonical mechanisms of 
EMT. The epicardium as discussed earlier is not a typical epithelial tissue because its 
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lineage is traced to a mesothelial origin. Support for this view comes from data identifying 
expression of mesenchymal markers like vimentin in the epicardial layer (Wu et al., 2010). 
In an effort to understand epicardial EMT various laboratories have looked at prototypical 
proteins of EMT in the epicardium. Downregulation of e-cadherin is considered a hallmark 
event to initiate EMT. In the epicardium it has been found that upregulation of e-cadherin 
leads to disruption of epicardial EMT. Two molecules in the epicardium seem to regulate e-
cadherin expression, VCAM1 and Wt1.  VCAM1 was observed to promote the epithelial -
like state of epicardial cells by decreasing the generation of stress fiber and maintaining  
expression of e-cadherin. The effects of VCAM1 in epicardial cells were found to 
counteract the EMT promoting effects of TGFβ3 (Dokic and Dettman, 2006). The other 
molecule found to regulate epicardial EMT though modulation of e-cadherin expression is 
Wt1. Mouse embryos lacking Wt1 specifically in the epicardium by deletion with Gata5Cre 
were found to have defects in EMT yielding a smaller heart and malformation of the 
coronary vessels. Hearts lacking Wt1 were shown to have an increase in amounts of e-
cadherin expression within the epicardial layer, suggesting that downregulation of e-
cadherin is important for Wt1-induced EMT. Wt1 binding sequences were found within the 
e-cadherin promoter and ChIP analysis confirmed the existence of the interaction in vivo. 
Additionally, Wt1 directly binds and regulates expression of Snail1, another gene that is 
typically involved in canonical EMT (Martinez-Estrada et al., 2010). Other known 
regulators of EMT are found to be expressed in the epicardial layer. For example , Slug is 
expressed in all cells of the epicardium and it has been proposed to promote competency of 
epicardial cells to undergo EMT, but no functional experiments have been done to prove 
this hypothesis (Carmona et al., 2000). Another regulator or epicardial EMT in chicken is 
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ETS1/2. Antisense oligonucleotides for ETS1/2 halted EMT of epicardial cells and lead to 
multiple cardiac defects including a thinner myocardium. Growth factors have also been 
shown to control epicardial EMT (Lie-Venema et al., 2003). TGFβ signaling has been 
implicated in modulating EMT of epicardial cells, but it is not yet clear whether it 
stimulates or inhibits EMT since studies from different researchers are contradictory. 
Studies in the chicken embryo showed that addition of TGFβ2 and TGFβ3 inhibit EMT of 
epicardial monolayers and EMT of explanted hearts. This contrasts with other results that 
showed that treatment with TGFβ3 to chicken explanted hearts activated EMT. It is 
important to mention that most studies suggested that TGFβ signaling promotes EMT and 
inhibits the epicardial phenotype (Compton et al., 2006; Dokic and Dettman, 2006; 
Morabito et al., 2001). These findings support the idea that epicardial EMT occurs via a 
canonical EMT mechanism. Recent reports on the effect of β-catenin in epicardial EMT 
argue that asymmetrical cell division is part of the mechanism. β-catenin epicardial 
knockouts were found to have decreased amounts of EMT causing defects in cardiac 
morphology. This decrease in EMT was due to the structural effect of β-catenin in 
regulating the spindle orientation of epicardial asymmetrical divisions (Wu et al., 2010). 
This data taken together raises new questions. How are the mechanisms of asymmetrical cell  
division coupled with the prototypical mechanisms of EMT? Traditionally defects in 
epicardial EMT have been interpreted in the field as a failure of the epicardial -derived cell 
to coalesce into the subepicardium and/or invade the myocardium. This interpretation makes 
it very difficult to distinguish between varied phenotypes that could account for this result. 
For example, EMT defects, migration defects or both. Another interesting question is what 
could be the role, if any, of the subepicardial mesenchyme during EMT?  
21 
 
Subsequent to EMT, the epicardial derived cell migrates further into the myocardium 
to reach their final destination within the heart architecture. Smooth muscle cells and 
pericytes migrate to the periphery of the coronary vessels and the interstitial fibroblasts 
migrate within the cardiac myocytes. Mechanisms regulating this migration are poorly 
understood. One could imagine that these cells require a very complicated array of signals 
to move toward their final destination. These signals should control polarity, differentiation 
and chemotacticity of the EPDCs. Not to mention that the length of the migration could , in 
certain cases, be very long; therefore, extended mechanisms of induction are required to 
reach the final developmental goal. Very few researchers have examined the mechanisms of 
epicardial-derived cells migration. One researcher showed that absence of connexin 43 
caused decrease migration of EPDCs. This was due to the disruption of cell polarity (Rhee 
et al., 2009). The obstruction of migration in these cells leads to secondary heart 
malformations. The final fate of cells lacking connexin43 was not determined. PDGFRβ was 
also found to regulate epicardial-derived cell migration (Mellgren et al., 2008). Defects in 
formation of the coronary vessels and absence of regional vascular smooth muscle in hearts 
with epicardial deletion of PDGFRβ lead to the hypothesis that PDGFRβ is important for 
migration of specifically vsmcs. Expression of EphrinB1 and EphrinB3 localized to the 
epicardium of the chick embryo. Explant cultures of epicardial monolayers treated with 
EprhinB1 was able to induce migration of the monolayer (Wengerhoff et al., 2010).  
Many questions arise from these experiments. How is migration of smooth muscle 
cells versus interstitial fibroblast directed towards different compartments of the heart? 
When does terminal differentiation of EPDCs occur? Are the epicardial derived cells 
predetermined to a cell fate before undergoing EMT? What are the signals that direct 
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differential migration and differentiation of migratory EPDCs? How do epicardial-derived 
smooth muscle cells couple their insertion into the coronary vessels’ architecture and vice 
versa? What is the function of the epicardial-derived interstitial fibroblast during 
development and after? Importantly, many of the molecules found to play a role in 
epicardial mesenchymal transformation or migration have also been implicated in regulating 
differentiation of these cells into smooth muscle cells, but none have been correlated with 
the generation of cardiac fibroblast (Mahtab et al., 2009; Mellgren et al., 2008; Wengerhoff 
et al., 2010). It is important to mention that epicardial-derived cells also have been found to 
give rise to cardiac muscle in mice. Recently, two labs reported that epicardial-derived cells 
in the mouse could give rise to myocardial cells. They used inducible Cre-Loxp lineage 
tracing to follow the fate of the epicardial cells in mouse embryos. Although their 
conclusions are very interesting, the results are controversial because the Cre markers used 
are not exclusive to the epicardium and continue to be expressed in the mouse heart at later 
stages (Cai et al., 2008; Zhou et al., 2008a).  
Previously, I mentioned that the developing heart has different mechanisms to induce 
myocardial proliferation throughout development. During midgestation, for example, FGFs 
emanating from the epicardium activate FGF receptors directly in the cardiac myocytes to 
induce proliferation (Lavine et al., 2005). Little was known about the mechanism of cardiac 
expansion during the late embryonic stages. However, it was recently shown that cardiac 
fibroblasts are required for the rapid proliferation of cardiomyocytes during late gestation. A 
surge in the development of embryonic cardiac fibroblast correlates with the late gestation 
cardiac myocyte proliferation. Srivastava et al showed that embryonic cardiac myocytes , but 
not adult cardiac myocytes, could induce myocardial proliferation. It was elucidated that 
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fibronectin and collagen produced by the cardiac fibroblast signals to the cardiac myocyte 
through binding the β1 integrin receptor. This interaction is promoted by HBEGF produced 
by cardiac fibroblast. This data point to HBEGF as the growth factor needed during late 
gestation to induce myocardial proliferation. Conditional deletion of β1 integrin in the 
myocardium lead to the formation of a smaller heart suggesting that the interaction between 
ECM and β1 integrin is seminal to cardiomyocyte proliferation during late embryonic 
development (Ieda et al., 2009). Interestingly, the major source of embryonic cardiac 
fibroblasts is provided by the epicardial-derived cells. Furthermore, epicardial EMT and 
migration occurs actively from E13.5 to E17.5 in the embryo which correlates with the time 
of ventricular compaction. As with the myocardial knockout of β1 integrin , many mouse 
models of proteins defective in epicardial EMT and migration mentioned previously develop 
a smaller heart. This observation suggests that the amount of embryonic cardiac fibroblasts 
migrating into the heart might be critical to reach the proper size of the heart. The role of 
cardiac fibroblasts during heart development is not well studied. In the adult, cardiac 
fibroblasts comprises the largest non-myocyte population of cells in the heart and is known 
to be necessary for extracellular matrix synthesis, a very important component of the cardiac 
skeleton (Snider et al., 2009).   
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Figure 1.  
 
Overview of epicardial development. (A) At E9.5 the heart is looped and the 
proepicardium is a bundle of cells attached to the ventral body wall. The yellow square 
marks the area zoomed in (B). (B) The heart is only composed of two layers: the 
endocardium (pink) and the myocardium (cyan). Proepicardial villous cysts (red) grow 
allowing proepicardial cells to contact the heart or travel through the pericardial fluid to 
contact the heart. (C) Proepicardial cells migrate in a gradient from base to apex over the 
surface of the heart covering it. (D) As the epicardium covers the heart, the subepicardial 
mesenchyme (orange) forms to provide a space for a subset of epicardial cells to undergo an 
epithelial to mesenchymal transition. The cells that undergo EMT and migrate are termed 
EPDCs. Epicardial cells differentiate into either vascular smooth muscle cells (red) or 
cardiac fibroblasts (green). Simultaneously, the primitive vascular tree formed by sprouting 
of the sinous venosus also grows in a gradient from base to apex (blue). (E) The heart 
continues growing and the vascular plexus remodels by incorporating the vascular smooth 
muscle cells. The yellow circle and square marks a zoomed area shown in (F). (F) Shows 
the lineage fate of the epicardial cells and their final location in the heart. Vascular smooth 
muscle cells are recruited to the endothelial tubes and cardiac fibroblast become part of the 
fibrous skeleton of the heart. (G) Legend.  
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Abstract 
 
The epicardium serves as a source of growth factors that regulate myocardial 
proliferation and as a source of epicardial-derived cells, interstitial cardiac fibroblasts and 
perivascular cells, which populate the compact myocardium. In addition to epicardial-
derived growth factors, such as fibroblast growth factor 9 (FGF9), cardiac fibroblasts are 
also necessary for myocardial growth. The mechanisms that regulate epicardial function 
during development and the mechanisms that regulate the formation of epicardial-derived 
cells are poorly understood. Here, we identify a myocardial to epicardial fibroblast 
growth factor (FGF) signal, mediated by FGF10 and FGFR2b that is essential for 
movement of cardiac fibroblasts into the compact myocardium. Inactivation of this 
signaling pathway results in fewer epicardial derived cells within the compact 
myocardium, decreased myocardial proliferation and a resulting smaller, thin-walled 
heart. 
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Introduction 
 
The epicardium comprises the outer layer of the heart and provides a source of 
cardiac fibroblasts, vascular smooth muscle cells and pericytes during heart development 
(Cai et al., 2008; Dettman et al., 1998; Marguerie et al., 2006; Merki et al., 2005; Mikawa 
and Fischman, 1992 ; Mikawa and Gourdie, 1996; Snider et al., 2009). The formation of 
the epicardial layer begins after heart looping at E9.5 in the mouse (Kalman et al., 1995). 
Epicardial cells arise from the proepicardial organ, which is a transient structure located 
close to the sinus venosus on the ventral body wall (Hiruma and Hirakow, 1989; Vincent 
and Buckingham, 2010). Cells from the proepicardium migrate to the atrioventricular 
groove and then from the base of the heart to the apex, covering the heart as a single cell 
layer. Concurrently, a capillary plexus grows from the dorsal atrioventricular groove and 
expands towards the apex and ventrally to envelope the entire heart (Kattan et al., 2004; 
Lavine et al., 2006; Red-Horse et al., 2010). As epicardial cells migrate to cover the 
heart, a subset of epicardial cells undergo epithelial to mesenchymal transitions (EMT) 
and delaminate from the epicardium. These cells are termed epicardial derived cells 
(EPDCs). Once EPDCs acquire mesenchymal phenotype they migrate further into the 
compact myocardium where they differentiate into smooth muscle cells and cardiac 
fibroblasts. PDFGRβ, Alk5 are factors that regulate epicardial-derived vascular smooth 
muscle cells (Mellgren et al., 2008; Sridurongrit et al., 2008). In contrast, factors that 
regulate migration of cardiac fibroblast have not been identified. These differentiated 
smooth muscle cells and cardiac fibroblasts become part of the mature coronary 
vasculature and interstitial mesenchyme of the heart.  
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The FGF family is comprised of 18 signaling ligands and four receptors (FGFRs) 
(Itoh and Ornitz, 2008; Ornitz and Itoh, 2001; Turner and Grose, 2010). Fgfr1, Fgfr2 and 
Fgfr3 undergo alternative splicing that results in b and c splice variants (Dell and 
Williams, 1992; Werner et al., 1992). The b splice variants are preferentially expressed in 
epithelial and epithelial-like tissues, such as the epicardium (Marguerie et al., 2006). In 
contrast, c splice variants are preferentially expressed in mesenchymal tissues. FGF 
ligands are classified in subfamilies based on phylogenetic similarities. Members of each 
subfamily of FGFs share similar biochemical properties, such as affinity for specific 
FGFRs and FGFR splice variants (Itoh and Ornitz, 2004). FGFR2c is efficiently activated 
by members of the FGF9 subfamily (FGF9, FGF16 and FGF20) (Ornitz et al., 1996; 
Zhang et al., 2006). In contrast, FGF3, FGF7, FGF10 and FGF22 are ligands that activate 
FGFR2b. Downstream FGF signal transduction can proceed via three main pathways: 
Ras/MAPK pathway, phospholipase Cγ (PLCγ)/Ca2+ pathway, and the PI3 kinase/Akt 
pathway (Eswarakumar et al., 2005; Lemmon and Schlessinger, 2010).  
The expression of several FGFs and FGFRs in cardiac and vascular mesoderm, 
mesothelium and endoderm suggests an important role for these molecules in 
development of the heart. In zebrafish and avian models, FGF signaling has been 
implicated as important for epicardial cells to undergo EMT, to enter the myocardium, 
and potentially to differentiate into coronary smooth muscle cells, interstitial cardiac 
fibroblasts, coronary endothelial cells and cardiomyocytes (Lepilina et al., 2006; Mikawa 
and Gourdie, 1996; Morabito et al., 2001; Perez-Pomares et al., 2002). The FGF ligands, 
FGF1, FGF2 and FGF7 were shown to stimulate EMT in cultured epicardial cells 
(Morabito et al., 2001) and pharmacological inhibition of FGF signaling impaired 
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epicardial EMT (Pennisi and Mikawa, 2009); however, retroviral expression of a 
dominant negative FGFR1 in epicardial and endothelial precursors in the proepicardial 
organ did not affect epicardial EMT but did impair the progeny of proepicardial-derived 
cells from invading the myocardium (Pennisi and Mikawa, 2009). These studies suggest 
that FGF signaling is necessary for epicardial and endothelial development but do not 
define the precise FGF signaling pathways that regulate each of these lineages or 
determine whether signaling is direct or indirect.  
In previous studies, we identified an epicardial to myocardial FGF signaling 
pathway, in which FGF9, expressed in the epicardium, signals to FGFR1c and FGFR2c 
in the myocardium to control myocardial proliferation and indirectly, vascular formation 
(Lavine et al., 2005). Several studies have identified expression of Fgf7 and Fgf10 in the 
developing myocardium and one study showed that mice lacking the b splice variant of 
Fgfr2 (Fgfr2b
-/-
) developed a thin-walled heart (Marguerie et al., 2006; Morabito et al., 
2001). These observations suggest that FGF signals emanating from the myocardium 
might directly regulate epicardial development or function. In this study, we show that 
FGF10 signals to the epicardium through FGFR1 and FGFR2b. In turn, these receptors 
control movement of EPDCs into the compact myocardium. Inactivation of this pathway 
results in fewer EPDCs within the compact myocardium and results in reduced 
cardiomyocyte proliferation and a smaller heart. 
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Results 
FGF10 signaling to the epicardium regulates heart size. 
The phenotype of Fgfr2b
-/-
 mice and the presence of appropriate ligand expression 
in the heart suggested that FGF signaling might regulate epicardial function and 
indirectly myocardial development. Such a signal, from cardiomyocytes, fibroblast or 
vascular cells in the compact myocardium may constitute a feedback loop to the 
epicardium to control heart size during development. To test the hypothesis that a 
myocardial to epicardial signal could regulate development of the heart, we measured the 
cross-sectional area of the whole heart and the thickness of the compact myocardium in 
Fgfr2b
-/-
, Fgf7
-/- 
and Fgf10
-/-
 embryos at several developmental time points. At earlier 
stages (E13.5 to E15.5), Fgfr2b
-/-
 hearts appeared normal in external morphology (data 
not shown), but at embryonic day 17.5 (E17.5), Fgfr2b
-/-
 embryos and
 
Fgf10
-/- 
embryos 
both appeared smaller (Figure 1A-D). The width of the compact myocardium of Fgfr2b
-/-
 
embryos as shown by (Marguerie et al., 2006) and
 
Fgf10
-/- 
embryos were significantly 
(p<0.02, p< 0.003, respectively) thinner than age-matched control embryos (Figure 1A’-
D’). Fgf7-/- embryos did not show a significant difference in thickness of the compact 
myocardium. We were able to generate two Fgf7
-/-
;Fgf10
-/- 
embryos at E17.5, and the 
hearts of both appeared smaller in size compared to Fgf10
-/-
 hearts, suggesting possible 
redundancy with FGF7. In utero echocardiography also showed a decrease in diastolic 
wall thickness in E17.5 Fgfr2b
-/- 
hearts when compared to control littermates (Figure 1G-
J and supplemental Figure 1). Consistently, the interventricular septum of Fgfr2b
-/- 
hearts 
was also thinner (Figure 1K). We also examined the formation of coronary vessels in 
Fgfr2b
-/-
 and
 
Fgf10
-/- 
hearts. Endothelial vessels formed normally compared to controls 
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(Supplemental Figure 2). Taken together, these data suggest that FGF10
 
signals to 
FGFR2b during late gestation to control heart size.  
Based on these phenotypes, we hypothesized that FGFR2b should be expressed in 
epicardial cells and FGF10
 
should be expressed in cardiac myocytes or other cell-types 
within the compact myocardium. In situ hybridization localized Fgf10 mRNA expression 
within the myocardium of wild type hearts at E17.5 (Figure 2A-B). No expression was 
observed in Fgf10
-/-
 hearts or with a sense probe. FGFR2 protein expression was 
examined using an antibody that detects both the b and c splice forms (Figure 2C-D). In 
wild type hearts, FGFR2 expression was observed in both the epicardial layer and the 
myocardial layer. In contrast, in Fgfr2b
-/-
 hearts, the expression of FGFR2 was absent in 
the epicardial layer but present throughout the myocardium. This expression pattern 
supports a model in which myocardial derived FGF10 signals to FGFR2b in the 
epicardium to control heart size. Additionally, FGF10 could signal to other unidentified 
FGFR2b-expressing cells within the myocardium.  
Fgfr2b
-/-
 is a germline knockout with multiple developmental defects. Therefore, 
to determine whether FGFR2 signaling in epicardial cells and EPDCs could be 
responsible for the observed cardiac phenotypes in Fgfr2b
-/-
 embryos, we used Wt1-Cre 
to inactivate a floxed allele of Fgfr2 in the epicardium and in EPDCs (Figure 3). Because 
FGF10 can also signal to FGFR1b and FGFR1 and FGFR2 often show functional 
redundancy, we simultaneously inactivated conditional alleles of both Fgfr1 and Fgfr2. 
Mice with the genotype, Wt1-Cre, Fgfr1
f/f
, Fgfr2
f/f
 (referred to as Fgfr1/2
Wt1-Cre
) showed a 
thin-walled compact myocardium similar to that seen in Fgfr2b
-/- 
and Fgf10
-/-
 embryos 
(Figure 3E). However, mice conditionally lacking only Fgfr1 or Fgfr2 did not show a 
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significant decreased wall thickness, demonstrating functional redundancy of these 
receptors. In addition, total heart size in Fgfr1/2
Wt1-Cre
 embryos was decreased compared 
to heterozygous control embryos when normalized to body weight (Figure 3F). The more 
severe phenotype of Fgfr2b
-/- 
hearts, compared to Fgfr2
Wt1-Cre
 hearts, could be a 
consequence of developmental defects intrinsic or extrinsic to the heart.  
To account for the observed small size of the heart in Fgfr1/2
Wt1-Cre
 and Fgf10
-/- 
embryos, we examined myocardial proliferation and cell death. Examination of BrdU 
incorporation showed a significant decrease in proliferation when compared to controls at 
E15.5 and E17.5 (Figure 4) in Fgfr1/2
Wt1-Cre
 hearts. These results suggest that FGF10 
controls epicardial development or function that in turn indirectly regulates myocardial 
growth. Immunostaining for active Caspase 3 expression did not show any differences 
between controls and Fgfr1/2
Wt1-Cre
 or Fgf10
-/- 
hearts (Supplemental Figure 3).  
Regulation of epicardial development by FGF signaling. 
To determine whether loss of epicardial FGFR1 and FGFR2 in Fgfr1/2
Wt1-Cre
 mice 
affects epicardial development we examined the rate of proliferation of epicardial cells 
and the number of epicardial-derived cells localized within the compact myocardium in 
Fgfr1/2
Wt1-Cre
 and Fgf10
-/-
 were counted. At E17.5, there was no change in proliferation 
of epicardial cells between Fgfr1/2
Wt1-Cre 
mice and control littermates (Figure 4D). To 
determine if epicardial EMT, delamination from the epicardium, or EPDC migration was 
defective in Fgfr1/2
Wt1-Cre
 and Fgf10
-/- 
hearts, we examined the expression of Wt1, a 
protein expressed in epicardial cells and EPDCs (Figure 5A-D). In control hearts at 
E17.5, 15% of cells within the compact myocardium expressed Wt1. In contrast, in 
Fgfr1/2
Wt1-Cre
 and Fgf10
-/- 
hearts there were significantly (p< 0.005 and p< 0.03, 
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respectively) fewer (9%) cells in the compact myocardium that expressed Wt1. In 
addition, Wt1 expression at E13.5 was also significantly reduced in the myocardial area 
of FGFR2b
-/-
 and Fgf10
-/-
 hearts (Supplemental Figure 4). However, Wt1 expression in 
the epicardium appeared normal. To further determine whether epicardial EMT could be 
impaired, expression of E-cadherin, a factor involved in epicardial EMT, was examined. 
Like Wt1, E-cadherin expression appeared normal in the epicardium of Fgfr1/2
Wt1-Cre
 and 
Fgf10
-/- 
hearts (Supplemental Figure 5).  
A prediction of these observations is that activation of the epicardial FGF 
signaling pathways would increase migration of EPDCs within the compact myocardium. 
We therefore examined the expression of Wt1 in embryos induced to overexpress FGF10 
(Figure 5E-G). Embryos containing the Rosa26-rtTA; TetO-Fgf10 alleles were induced 
with doxycycline from E15.5 to E17.5 to upregulate expression of Fgf10 throughout most 
embryonic tissues. Hearts from these embryos showed a 10% (p< 0.05) increase in the 
number of Wt1 positive cells within the myocardium compared to wild type or 
heterozygous littermate controls.  
To further characterize the EPDCs within the myocardium, hearts were stained 
with an antibody to vimentin, a marker of cardiac fibroblasts (Figure 5H-K). Consistent 
with the decreased number of Wt1-positive cells within the myocardium of Fgfr1/2
Wt1-Cre
 
and Fgf10
-/- 
hearts, the number of vimentin-positive cells was also decreased in 
Fgfr1/2
Wt1-Cre
 and Fgf10
-/- 
hearts compared to controls. These loss-of-function and gain-
of-function studies
 
support a model in which FGF signaling regulates migration of a 
subset of EPDCs (that will become cardiac fibroblasts) into the compact myocardium.  
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FGF signaling regulates EPDC migration. 
To determine whether FGF10 signaling regulates migration of EPDCs into the 
myocardium, hearts were labeled with carboxyfluorescein diacetate succinimidyl ester 
(CFSE) to label epicardial cells (Morabito et al., 2001), allowing their location to be 
imaged following explant culture. CFSE is permeable to cells, but once inside a cell, 
esterases cleave the molecule trapping it in the cytosol. To determine whether epicardial 
cells could be specifically labeled, dissected E17.5 wild type hearts were treated with 
CFSE for 1 hr and then fixed, sectioned and immunostained for Wt1. CFSE and Wt1 
were co-localized in the epicardial cell layer, and Wt1 was also present in EPDCs that 
had already migrated into the myocardium prior to labeling with CFSE (Figure 6A-C, 
arrows highlight Wt1
+ 
cells that have already migrated into the myocardium). To 
determine whether FGF10 activated FGFR signaling in CFSE-labeled cells, CFSE-
labeled and FGF10-treated explants were stained for p-Erk, a downstream target of 
activated FGFRs. Exposure to FGF10 for 48 hrs resulted in an increase in p-Erk labeling 
of CSFE
+
 cells in the epicardium and myocardium, but not of CFSE
-
 cells within the 
compact myocardium (Figure 6D-F). This increase in p-Erk labeling in response to 
FGF10 was blocked by treatment with the FGFR inhibitor PD173074. 
To determine if EPDC migration into the myocardium responded to FGF10, 
E17.5 heart explants were treated with CFSE for 1 hr, washed, and then cultured for 48 hr 
with or without FGF10 and PD173074. In addition, to determine the specificity of FGF 
signaling, explants were also treated with FGF9, a ligand that is expressed in the 
epicardium that signals to cardiomyocytes (Figure 6G-K). In response to treatment with 
FGF10, explants showed a significant (p< 0.002) increase in CFSE-labeled cells within 
the sub-epicardial space and compact myocardium. Addition of the FGFR inhibitor, 
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PD173074, along with FGF10 resulted in a significant (p< 0.005) decrease in CFSE-
labeled cells within the sub-epicardial space and compact myocardium, while treatment 
of explants with FGF9 had no effect on migration of CFSE-labeled epicardial cells 
(Figure 6K, O). Taken together, these data demonstrate that FGF10 is sufficient to 
increase CFSE-labeled cell movement into the myocardium.  
To determine whether FGF10 had an effect on EPDCs that had already migrated 
into the myocardium prior to CFSE labeling, the number of Wt1
+
, CFSE
-
 cells in FGF10-
treated explanted hearts were counted. Consistent with a model in which FGF10 signals 
only to FGFR1b/FGFR2b in epicardial cells, there was no change in the number of Wt
+
, 
CFSE
-
, EPDCs following FGF10 treatment (Figure 6L-O). 
FGF10 regulates formation of cardiac fibroblasts  
During heart development, epicardial cells give rise to cardiac fibroblasts and 
smooth muscle cells that populate the compact myocardium. Under specialized 
conditions, such as following injury, epicardial cells may also give rise to cardiomyocytes 
and endothelial cells. To determine the fate of epicardial cells that respond to FGF10, 
explants labeled with CFSE and treated with FGF10 for 48 hr were sectioned and 
immunostained for markers of specific cardiac lineages including myocytes, endothelial 
cells, smooth muscle cells and fibroblasts (Figure 7). CFSE-labeled cells did not co-
immunostain with antibodies to myocytes, endothelial cells, or smooth muscle cells, but 
did co-label with an antibody to vimentin, a marker expressed on fibroblasts (Figure 7D-
F). These data suggest that FGF10 promotes formation and movement of EPDCs that 
preferentially differentiate into cardiac fibroblasts.  
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To determine whether FGF signaling could affect the motility of epicardial cells, 
live-imaging was used to monitor movement of isolated epicardial cells from Fgfr2b
-/- 
and wild type hearts and hearts treated with vehicle or PD173074 (Figure 8). Epicardial 
cells from Fgfr2b
-/-
 hearts showed a significantly (p< 0.02) shorter displacement, but 
similar distance traveled when compared to wild type epicardial cells. Consistent with 
this result, epicardial cells treated with PD173074 also showed a significantly (p< 0.001) 
shorter displacement and no change in the distance traveled. Addition of FGF10 to 
epicardial cell cultures did not increase epicardial cell motility (data not shown), 
indicating that FGF signaling was likely saturated in these cultures. 
Discussion 
Epicardial derived cells give rise to several cell types that populate the compact 
myocardium. These include interstitial fibroblasts, perivascular cells and smooth muscle 
cells. EPDCs also regulate growth of the myocardium but the factors that regulate their 
differentiation and their migration into the myocardium are poorly understood. We show 
that during late embryonic development, FGF10 signals to epicardial and epicardial 
derived cells through FGFR2b to induce their migration into the myocardium.  
In mice conditionally lacking Fgfr1 and Fgfr2 in epicardial cells, or lacking 
Fgf10, significantly fewer EPDCs were observed within the compact myocardium. 
Several mechanisms could result in this phenotype including: defects in epicardial EMT; 
failure of EPDCs to migrate into the compact myocardium; or increased death of EPDCs. 
EMT is a complex process that requires the dissolution of cell-cell junctions, loss of 
apical-basal polarity, and finally the modification of cytoskeletal proteins to a 
mesenchymal phenotype that permits, in the case of epicardial cells, movement into the 
53 
 
subepicardial space (reviewed in Thiery et al., 2009). Although the precise signals and 
mechanisms governing epicardial EMT are not known, epicardial EMT requires β-
catenin-dependent asymmetrical cell division (Wu et al., 2010) and Wt1 mediated 
repression of E-cadherin and upregulation of snail (Martinez-Estrada et al., 2010). In 
mice lacking FGF10 or epicardial FGFR1/2, epicardial EMT appears to occur normally, 
as proliferation and Wt1, snail and β-catenin expression were not changed in epicardial 
cells. Furthermore, increased apoptosis of EPDCs, which could also explain fewer of 
these cells within the myocardium, is also unlikely, since staining for activated caspase 3 
revealed no increase in cell death in Fgfr1r2
Wt1-Cre
 and Fgf10
-/- 
hearts.  
Following epicardial EMT, EPDCs migrate further into the myocardium and 
differentiate into either smooth muscle cells or cardiac fibroblasts. The mechanisms that 
direct EPDCs into the compact myocardium are not known, however, our data suggests 
that FGF10/FGFR2b signaling may regulate epicardial movement into the myocardium. 
In primary epicardial cell cultures lacking Fgfr2b or treated with FGFR kinase inhibitors, 
we observed a reduction in cell displacement. These results could be explained by FGF10 
functioning as a chemotactic factor or regulating cell motility (displacement in epicardial 
cultures). In vivo, FGF10 is unlikely to regulate directional migration of EPDCs in the 
heart, because of its diffuse expression throughout the compact myocardium. In contrast, 
in the lung, Fgf10 is expressed focally in mesenchyme where it functions to induce 
epithelial branching and migration towards the source of FGF10 (Weaver et al., 2000). In 
addition, in heart explants, addition of FGF10 protein to the media induced EPDC 
migration into the compact myocardium, suggesting that focal expression of FGF10 is 
not required. Recently, it was demonstrated that FGF-regulated increases in cell motility 
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could have net positive effects on directional cell movements required for embryonic axis 
elongation (Benazeraf et al., 2010). It is thus possible that FGF10 regulated cell motility 
could account for the specific influx of cardiac fibroblasts into the compact myocardium. 
Other factors like PDGFRβ and Alk5, that regulate either epicardial migration or EMT, 
have been found to specifically affect vascular smooth muscle cell recruitment or 
differentiation, but do not have reported effects on cardiac fibroblasts (Mellgren et al., 
2008; Sridurongrit et al., 2008). We posit that FGF preferentially regulates migration of 
cardiac fibroblasts and PDGFβ preferentially regulates migration of vascular smooth 
muscle cells.  
FGFs often signal bidirectionally during organogenesis, for example in limb bud 
and lung development (Morrisey and Hogan, 2010; Yang, 2009; Zeller et al., 2009). 
During midgestation heart development, communication between the epicardium and 
myocardium appears necessary to regulate the ultimate size of the heart. Although 
reciprocal FGF signaling between mesenchymal and epicardial tissues is important for 
heart development, other signaling molecules, direct cell-cell contact, and physiological 
factors are likely to interact with FGF signaling to coordinate heart size with growth of 
the embryo and its physiological requirements.  
Multiple signals regulate growth of the myocardium (Sucov et al., 2009). Of 
these, epicardial derived FGF9 and FGF16 are factors that directly signal to FGFRs 
expressed in cardiomyocytes. Although myocardial proliferation is reduced in mice 
lacking FGF9 (Lavine et al., 2005), FGF16 (Hotta et al., 2008) or lacking both FGF9 and 
FGF16 (unpublished), proliferation is clearly not arrested. This indicates that other 
factors must act in parallel to FGF9/16 to regulate myocardial proliferation. Other factors 
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could include other growth factors such as WNT9b (Merki et al., 2005), or direct 
interactions between cells. Recently, cardiac fibroblasts were shown to directly induce 
myocardial proliferation through a mechanism involving HBEGF and integrin signaling 
(Ieda et al., 2009). The major source of embryonic cardiac fibroblasts during 
development is EPDCs. In our model, inactivation of FGF signaling in EPDCs leads to a 
decrease in EPDCs that specifically give rise to cardiac fibroblasts within the compact 
myocardium. Interestingly, we also observed a coincident decrease in myocardial 
proliferation and a reduction in heart size. We posit that decreased myocardial 
proliferation in hearts lacking epicardial FGF signaling could result from indirect 
consequences of decreased numbers of interstitial cardiac fibroblasts. This is consistent 
with small heart size phenotypes observed in other mutations that disrupt proepicardial 
migration, defects in epicardial EMT and EPDC migration into the myocardium 
(Martinez-Estrada et al., 2010; Rhee et al., 2009; Wu et al., 2010).  
In the studies presented here, the Fgfr2b
-/- 
hearts appear to have a more severe 
(smaller heart) phenotype than Fgfr1/2
Wt1-Cre
 hearts. Fgfr2b
-/- 
is a germline knockout; 
therefore deletion of Fgfr2b is complete and can act over a longer period of time 
compared to a conditional knockout. In addition, other developmental defects could 
indirectly contribute to the cardiac phenotype in Fgfr2b
-/- 
hearts.  
Understanding mechanisms that regulate myocardial growth have historically 
been the focus of much research because of the importance of the cardiomyocyte to heart 
homeostasis and response to injury. One of the challenges that have slowed advances in 
the treatment of the injured heat is the limited ability of adult cardiomyocytes to 
proliferate. Recent studies on epicardial cells and their ability to differentiate into various 
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cell types and communicate with cardiac myocytes have suggested new therapeutic 
targets to treat heart disease. Future studies are needed to determine whether 
FGF10/FGFR2b signaling occurs in the adult heart under homeostatic or pathological 
conditions and whether this signaling pathway could be therapeutically manipulated to 
promote cardiac protection or regeneration.  
Materials and Methods 
Mice 
Mouse lines used: Fgfr2b
-/- 
(Revest et al., 2001), Fgf7
-/-
 (Guo et al., 1996), Fgf10
-/-
 
(Min et al., 1998), Wt1-Cre (Min et al., 1998), Fgfr1
f/f
 (Trokovic et al., 2003), Fgfr2
f/f
 (Yu 
et al., 2003), Rosa26-rtTA (Belteki et al., 2005), TetO-Fgf10 (Clark et al., 2001). 
Histology  
Paraffin sections (5µm) were stained with hematoxilin and eosin (H&E) for 
general visualization. Myocardial area was calculated with the contouring tool using 
Canvas X software. Cross-sectional area of the heart was defined as the measure of total 
muscle including both chambers in one mid-frontal section. Atrial area was not included. 
In Fgfr1
Wt1-Cre
, Fgfr2
Wt1-Cre
 and Fgfr1/2
Wt1-Cre 
values were normalized to body weight by 
dividing area by total body weight. Heart wall thickness was calculated with the linear 
dimensioning tool in Canvas X software. Compact myocardial thickness was determined 
by averaging three measurements of the length from the subepicardial layer to the edge of 
the compact myocardium in histological sections from each embryo examined. Statistical 
significance was determined using the student’s t-test, with n representing number of 
embryonic hearts examined.  
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Immunohistochemistry and Immunofluorescence 
For immunohistochemistry, paraffin sections (5μm) were dewaxed, rehydrated, 
incubated in methanol/hydrogen peroxide, antigen unmasked, and blocked in 10% goat 
serum. Antigen unmasking was performed by incubating sections in 1% trypsin for 5 min 
at room temperature or by pressure cooking in citrate buffer for 15 min. Primary 
antibodies used were FGFR2 (rabbit IgG, Santa Cruz, sc-122), BrdU (mouse IgG, Becton 
and Dickinson, 1:100), activated caspase 3 (BD Pharmigen cat# 557035) and Snail1 (a 
gift from A. García de Herreros Madueno). Expression was visualized using the 
Histostatin SP broad spectrum (DAB) kit from Invitrogen (95-9643). 
Immunofluorescence was performed the same way excluding blocking endogenous 
peroxidase. Primary antibodies used were Wt1 (mouse IgG1κ, Dakocytomation, M3561), 
vimentin (mouse IgM, Abcam, ab20346), pERK (mouse IgG2a, Santa Cruz, sc-7383), 
desmin (mouse IgG1, Research Diagnostics Inc, RDI-PRO10519), pecam (rabbit IgG, 
Abcam, ab28364), smooth muscle cell actin (mouse IgG1-Cy3, Sigma, c-6198), E-
cadherin (mouse IgG2a, BDTransduction, #610181), b-catenin (mouse IgG1, 
BDTransduction, #610153) and troponin (mouse IgG2a, Developmental Studies 
Hybridoma Bank, CT3-s). Secondary antibodies were incubated for 1hr and visualized 
with a Zeiss confocal microscope or Zeiss apotome microscope.  
Staining for β-galactosidase was performed as described (Soriano, 1999).  
In Situ Hybridization 
Tissues were fixed in 4% formaldehyde, embedded in paraffin and sectioned (5 
μm). In situ hybridization was performed as previously described (Wilkinson, 1992). The 
Fgf10 in situ probe was provided by B. Hogan (Bellusci et al., 1997).  
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Proliferation Analysis 
For embryos, pregnant females at E15.5 and E17.5 were injected IP with BrdU 
(50 μg/g body weight), 30 minutes prior to sacrifice. BrdU immunohistochemistry was 
performed as described above. Sections were counterstained with hematoxylin. For 
statistical analysis, two areas from three different specimens were analyzed per stage. The 
number of BrdU-positive nuclei relative to the total number of nuclei was counted from 
two 63x fields per section. Data is shown as mean ± SD. 
For organ cultures, 6.4 ng/ml BrdU was added to the culture media 30 min prior 
to fixation. BrdU incorporation was detected by immunohistochemistry. After fixation, 
tissues were embeded in paraffin and sectioned. Immunohistochemistry was performed as 
described above.  
Heart explant culture 
Hearts were dissected under aseptic conditions at E17.5. Hearts were then labeled 
with 50mM CFSE (5-(and-6)-carboxy-2’,7’-dichlorofluorescein diacetate succinimidyl 
ester, Invitrogen, cat# C1165) for one hour and placed in glass scintillation vials 
containing 1 ml of media (DMEM, 2 µg/ml Heparin, antibiotic and antimycotic). Vehicle 
(0.25 μl/ml DMSO), FGF10 (10 nM, Peprotech Inc.), FGF9 (10 nM, Peprotech Inc.) or 
PD173074 (25 nM, Pfizer Inc.) was added to the vials. Vials were incubated for 48 h on a 
rocker at 37°C/5% CO2 with loose caps. Hearts were harvested, fixed in 10% formalin or 
4% formaldehide and embeded in paraffin prior to sectioning. 
Epicardial live imaging 
Hearts were dissected under aseptic conditions at E15.5 and set in 1% collagen 
coated delta T dishes (Fisher) over night in 350 µl of media (DMEM, 5% horse serum, 2 
µg/ml Heparin and antibiotic and antimycotic). Hearts were then removed from the dish 
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leaving foci of epicardial cells attached to the dish. Adherent cells were washed and 2 ml 
of media was added to the cultures. FGF inhibitor (PD173074, 22 nM) was added as 
indicated. Cultures were placed in a live imaging chamber on Leica DMI 6000B 
microscope and maintained at 37°C in 5% CO2. 20x images were taken every 10 min for 
a period of 24 h. Image series were taken with a camera Retiga Exi. Images were 
prepared and exported using the CIMAT software (C. Little, UMKC, Kansas City) 
.Images were analyzed using the Manual Tracking plugin for Image J software. X and Y 
coordinates and scaling were used to calculate the distance, displacement, speed and 
velocity of cells in culture.  
Acknowledgements 
We thank C. Smith and H. Wynder for technical support, Tom Broeckelman for 
helping with live imaging and A. García de Herreros Madueno for providing the antibody 
to Snail. We thank K. Choi, K. Lavine, P. Jay, R. Mecham and Y. Yin for critically 
reading the manuscript. This work was supported by NIH grant HD049808 and a gift 
from the Virginia Friedhofer Charitable Trust. 
  
60 
 
References 
 
Bellusci, S., Grindley, J., Emoto, H., Itoh, N., and Hogan, B.L. (1997). Fibroblast growth 
factor 10 (FGF10) and branching morphogenesis in the embryonic mouse lung. 
Development 124, 4867-4878. 
Belteki, G., Haigh, J., Kabacs, N., Haigh, K., Sison, K., Costantini, F., Whitsett, J., 
Quaggin, S.E., and Nagy, A. (2005). Conditional and inducible transgene expression in 
mice through the combinatorial use of Cre-mediated recombination and tetracycline 
induction. Nucleic Acids Res 33, e51. 
Benazeraf, B., Francois, P., Baker, R.E., Denans, N., Little, C.D., and Pourquie, O. 
(2010). A random cell motility gradient downstream of FGF controls elongation of an 
amniote embryo. Nature 466, 248-252. 
Cai, C.L., Martin, J.C., Sun, Y., Cui, L., Wang, L., Ouyang, K., Yang, L., Bu, L., Liang, 
X., Zhang, X., et al. (2008). A myocardial lineage derives from Tbx18 epicardial cells. 
Nature 454, 104-108. 
Clark, J.C., Tichelaar, J.W., Wert, S.E., Itoh, N., Perl, A.K., Stahlman, M.T., and 
Whitsett, J.A. (2001). FGF-10 disrupts lung morphogenesis and causes pulmonary 
adenomas in vivo. Am J Physiol Lung Cell Mol Physiol 280, L705-715. 
Dell, K., and Williams, L. (1992). A novel form of fibroblast growth factor receptor 2. J 
Biol Chem 267, 21225-21229. 
Dettman, R.W., Denetclaw, W., Jr., Ordahl, C.P., and Bristow, J. (1998). Common 
epicardial origin of coronary vascular smooth muscle, perivascular fibroblasts, and 
intermyocardial fibroblasts in the avian heart. Dev Biol 193, 169-181. 
61 
 
Eswarakumar, V.P., Lax, I., and Schlessinger, J. (2005). Cellular signaling by fibroblast 
growth factor receptors. Cytokine Growth Factor Rev 16, 139-149. 
Guo, L., Degenstein, L., and Fuchs, E. (1996). Keratinocyte growth factor is required for 
hair development but not for wound healing. Genes Dev 10, 165-175. 
Hiruma, T., and Hirakow, R. (1989). Epicardial formation in embryonic chick heart: 
computer-aided reconstruction, scanning, and transmission electron microscopic studies. 
American Journal of Anatomy 184, 129-138. 
Hotta, Y., Sasaki, S., Konishi, M., Kinoshita, H., Kuwahara, K., Nakao, K., and Itoh, N. 
(2008). Fgf16 is required for cardiomyocyte proliferation in the mouse embryonic heart. 
Developmental Dynamics 237, 2947-2954. 
Ieda, M., Tsuchihashi, T., Ivey, K.N., Ross, R.S., Hong, T.T., Shaw, R.M., and 
Srivastava, D. (2009). Cardiac fibroblasts regulate myocardial proliferation through beta1 
integrin signaling. Dev Cell 16, 233-244. 
Itoh, N., and Ornitz, D.M. (2004). Evolution of the Fgf and Fgfr gene families. Trends 
Genet 20, 563-569. 
Itoh, N., and Ornitz, D.M. (2008). Functional Evolutionary History of the Mouse Fgf 
Gene Family Developmental Dynamics 237, 18-27. 
Kalman, F., Viragh, S., and Modis, L. (1995). Cell surface glycoconjugates and the 
extracellular matrix of the developing mouse embryo epicardium. Anatomy and 
Embryology 191, 451-464. 
Kattan, J., Dettman, R.W., and Bristow, J. (2004). Formation and remodeling of the 
coronary vascular bed in the embryonic avian heart. Dev Dyn 230, 34-43. 
62 
 
Lavine, K.J., White, A.C., Park, C., Smith, C.S., Choi, K., Long, F., Hui, C.C., and 
Ornitz, D.M. (2006). Fibroblast growth factor signals regulate a wave of Hedgehog 
activation that is essential for coronary vascular development. Genes Dev 20, 1651-1666. 
Lavine, K.J., Yu, K., White, A.C., Zhang, X., Smith, C., Partanen, J., and Ornitz, D.M. 
(2005). Endocardial and epicardial derived FGF signals regulate myocardial proliferation 
and differentiation in vivo. Developmental Cell 8, 85-95. 
Lemmon, M.A., and Schlessinger, J. (2010). Cell signaling by receptor tyrosine kinases. 
Cell 141, 1117-1134. 
Lepilina, A., Coon, A.N., Kikuchi, K., Holdway, J.E., Roberts, R.W., Burns, C.G., and 
Poss, K.D. (2006). A dynamic epicardial injury response supports progenitor cell activity 
during zebrafish heart regeneration. Cell 127, 607-619. 
Marguerie, A., Bajolle, F., Zaffran, S., Brown, N.A., Dickson, C., Buckingham, M.E., 
and Kelly, R.G. (2006). Congenital heart defects in Fgfr2-IIIb and Fgf10 mutant mice. 
Cardiovasc Res 71, 50-60. 
Martinez-Estrada, O.M., Lettice, L.A., Essafi, A., Guadix, J.A., Slight, J., Velecela, V., 
Hall, E., Reichmann, J., Devenney, P.S., Hohenstein, P., et al. (2010). Wt1 is required for 
cardiovascular progenitor cell formation through transcriptional control of Snail and E-
cadherin. Nature Genetics 42, 89-93. 
Mellgren, A.M., Smith, C.L., Olsen, G.S., Eskiocak, B., Zhou, B., Kazi, M.N., Ruiz, 
F.R., Pu, W.T., and Tallquist, M.D. (2008). Platelet-derived growth factor receptor beta 
signaling is required for efficient epicardial cell migration and development of two 
distinct coronary vascular smooth muscle cell populations. Circ Res 103, 1393-1401. 
63 
 
Merki, E., Zamora, M., Raya, A., Kawakami, Y., Wang, J., Zhang, X., Burch, J., 
Kubalak, S.W., Kaliman, P., Belmonte, J.C., et al. (2005). Epicardial retinoid X receptor 
alpha is required for myocardial growth and coronary artery formation. Proc Natl Acad 
Sci U S A 102, 18455-18460. 
Mikawa, T., and Fischman, D.A. (1992). Retroviral analysis of cardiac morphogenesis: 
discontinuous formation of coronary vessels. Proc Natl Acad Sci U S A 89, 9504-9508. 
Mikawa, T., and Gourdie, R.G. (1996). Pericardial mesoderm generates a population of 
coronary smooth muscle cells migrating into the heart along with ingrowth of the 
epicardial organ. Dev Biol 174, 221-232. 
Min, H., Danilenko, D.M., Scully, S.A., Bolon, B., Ring, B.D., Tarpley, J.E., DeRose, 
M., and Simonet, W.S. (1998). Fgf-10 is required for both limb and lung development 
and exhibits striking functional similarity to Drosophila branchless. Genes Dev 12, 3156-
3161. 
Morabito, C.J., Dettman, R.W., Kattan, J., Collier, J.M., and Bristow, J. (2001). Positive 
and negative regulation of epicardial-mesenchymal transformation during avian heart 
development. Dev Biol 234, 204-215. 
Morrisey, E.E., and Hogan, B.L. (2010). Preparing for the first breath: genetic and 
cellular mechanisms in lung development. Dev Cell 18, 8-23. 
Ornitz, D.M., and Itoh, N. (2001). Fibroblast growth factors. Genome Biology 2, 
REVIEWS3005. 
Ornitz, D.M., Xu, J., Colvin, J.S., McEwen, D.G., MacArthur, C.A., Coulier, F., Gao, G., 
and Goldfarb, M. (1996). Receptor specificity of the fibroblast growth factor family. J 
Biol Chem 271, 15292-15297. 
64 
 
Pennisi, D.J., and Mikawa, T. (2009). FGFR-1 is required by epicardium-derived cells for 
myocardial invasion and correct coronary vascular lineage differentiation. Developmental 
Biology 328, 148-159. 
Perez-Pomares, J.M., Carmona, R., Gonzalez-Iriarte, M., Atencia, G., Wessels, A., and 
Munoz-Chapuli, R. (2002). Origin of coronary endothelial cells from epicardial 
mesothelium in avian embryos. Int J Dev Biol 46, 1005-1013. 
Red-Horse, K., Ueno, H., Weissman, I.L., and Krasnow, M.A. (2010). Coronary arteries 
form by developmental reprogramming of venous cells. Nature 464, 549-553. 
Revest, J.M., Spencer-Dene, B., Kerr, K., De Moerlooze, L., Rosewell, I., and Dickson, 
C. (2001). Fibroblast growth factor receptor 2-IIIb acts upstream of Shh and Fgf4 and is 
required for limb bud maintenance but not for the induction of Fgf8, Fgf10, Msx1, or 
Bmp4. Dev Biol 231, 47-62. 
Rhee, D.Y., Zhao, X.Q., Francis, R.J., Huang, G.Y., Mably, J.D., and Lo, C.W. (2009). 
Connexin 43 regulates epicardial cell polarity and migration in coronary vascular 
development. Development 136, 3185-3193. 
Snider, P., Standley, K.N., Wang, J., Azhar, M., Doetschman, T., and Conway, S.J. 
(2009). Origin of cardiac fibroblasts and the role of periostin. Circ Res 105, 934-947. 
Soriano, P. (1999). Generalized lacZ expression with the ROSA26 Cre reporter strain. 
Nat Genet 21, 70-71. 
Sridurongrit, S., Larsson, J., Schwartz, R., Ruiz-Lozano, P., and Kaartinen, V. (2008). 
Signaling via the Tgf-beta type I receptor Alk5 in heart development. Dev Biol 322, 208-
218. 
65 
 
Sucov, H.M., Gu, Y., Thomas, S., Li, P., and Pashmforoush, M. (2009). Epicardial 
control of myocardial proliferation and morphogenesis. Pediatr Cardiol 30, 617-625. 
Thiery, J.P., Acloque, H., Huang, R.Y., and Nieto, M.A. (2009). Epithelial-mesenchymal 
transitions in development and disease. Cell 139, 871-890. 
Trokovic, R., Trokovic, N., Hernesniemi, S., Pirvola, U., Vogt Weisenhorn, D.M., 
Rossant, J., McMahon, A.P., Wurst, W., and Partanen, J. (2003). FGFR1 is independently 
required in both developing mid- and hindbrain for sustained response to isthmic signals. 
Embo J 22, 1811-1823. 
Turner, N., and Grose, R. (2010). Fibroblast growth factor signalling: from development 
to cancer. Nat Rev Cancer 10, 116-129. 
Vincent, S.D., and Buckingham, M.E. (2010). How to Make a Heart The Origin and 
Regulation of Cardiac Progenitor Cells. Current Topics in Developmental Biology 90C, 
1-41. 
Weaver, M., Dunn, N.R., and Hogan, B.L. (2000). Bmp4 and Fgf10 play opposing roles 
during lung bud morphogenesis. Development 127, 2695-2704. 
Werner, S., Duan, D.S., de Vries, C., Peters, K.G., Johnson, D.E., and Williams, L.T. 
(1992). Differential splicing in the extracellular region of fibroblast growth factor 
receptor 1 generates receptor variants with different ligand-binding specificities. Mol Cell 
Biol 12, 82-88. 
Wilkinson, D.G. (1992). In situ hybridization: A practical approach (Oxford, IRL press). 
Wu, M., Smith, C.L., Hall, J.A., Lee, I., Luby-Phelps, K., and Tallquist, M.D. (2010). 
Epicardial spindle orientation controls cell entry into the myocardium. Dev Cell 19, 114-
125. 
66 
 
Yang, Y. (2009). Growth and patterning in the limb: signaling gradients make the 
decision. Sci Signal 2, pe3. 
Yu, K., Xu, J., Liu, Z., Sosic, D., Shao, J., Olson, E.N., Towler, D.A., and Ornitz, D.M. 
(2003). Conditional inactivation of FGF receptor 2 reveals an essential role for FGF 
signaling in the regulation of osteoblast function and bone growth. Development 130, 
3063-3074. 
Zeller, R., Lopez-Rios, J., and Zuniga, A. (2009). Vertebrate limb bud development: 
moving towards integrative analysis of organogenesis. Nat Rev Genet 10, 845-858. 
Zhang, X., Ibrahimi, O.A., Olsen, S.K., Umemori, H., Mohammadi, M., and Ornitz, D.M. 
(2006). Receptor specificity of the fibroblast growth factor family. The complete 
mammalian FGF family. J Biol Chem 281, 15694-15700. 
 
 
 
  
67 
 
Figures and Figure Legends 
 
Figure 1. 
 
 
 
 
  
68 
 
 
Figure 1. 
Fgfr2b and Fgf10 regulate heart size. (A-D, A’-D’) H&E staining of hearts at 
E17.5. Control (A,A’), Fgfr2b-/- (B,B’), Fgf7-/- (C,C’) and Fgf10-/- (D,D’). Dashed 
rectangle in (A-D) denotes magnified area in (A’-D’). (E) Quantification of the relative 
area of the heart. Control, n=8; Fgfr2b
-/-
, n=8, ** p<0.001; Fgf10
-/-
, n=8,
 
* p<0.02; Fgf7
-/-
, n=5. (F) Quantification of left ventricular wall thickness (red line in A’-D’). Fgfr2b-/-, 
n=6, *p<0.02; Fgf10
-/-
, n=9,
 
* p<0.003; Fgf7
-/-
, n=5. (G,H) Short axis in utero 
echocardiogram at E17.5 of control (G) and Fgfr2b
-/- 
heart (H). Area measured (dashed 
white lines) and wall thickness measured (yellow lines) are placed at end diastole 
according to the movie shown in supplemental Figure 1. LV (left ventricle); S (septum); 
RV (right ventricle). (I-K) Quantification of left ventricular posterior wall diameter at end 
diastole (LVPWd), n=7, ** p<0.0003; right ventricular posterior wall diameter at end 
diastole (RVPWd), n=7, *p<0.02; interventricular septum diameter at end diastole, n=7, 
** p<0.001. Scale bar: (A-D) 500µm, (A’-D’) 100µm. Control hearts are a mix of wild 
type, Fgfr2b
+/-
 and Fgf7
+/-
, Fgf10
+/-
. Asterisk indicates statistically significant difference 
compared with controls.  
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Figure 2. 
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Figure 2. 
Expression of Fgfr2b and Fgf10 in the left ventricle of the heart at E17.5. (A-B) 
Fgf10 in situ hybridization showing Fgf10 mRNA in cells within the myocardial area in 
controls, no expression of FGF10 was observed in Fgf10
-/-
 hearts. (C-D) 
Immunohistochemistry showing expression of FGFR2 throughout the heart in controls 
(C). In Fgfr2b
-/-
 heart
 
(D), FGFR2b is absent from the epicardial layer. Dashed lines 
denotes border between myocardial and epicardial layer. Scale bar: 20 µm. 
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Figure 3. 
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Figure 3. 
Decreased heart size after epicardial conditional inactivation of Fgfr1 and Fgfr2 
with Wt1-Cre. (A-D, A’-D’) H&E staining of E17.5 control (A,A’), Fgfr1Wt1-Cre (B,B’), 
Fgfr2
Wt1-Cre (C,C’), and Fgfr1/2Wt1-Cre (D,D’) hearts. Fgfr1/2Wt1-Cre hearts are smaller 
compared to controls and display a thinner compact myocardium. Dashed rectangle in 
(A-D) denotes magnified area in (A’-D’). (E) Quantification of the left ventricle wall 
thickness (red line in A’-D’). Control, n=14; Fgfr1Wt1-Cre, n=5; Fgfr2 Wt1-Cre, n=10; 
Fgfr1/2
Wt1-Cre
, n=9, ** p<0.001. Scale bar: (A-D) 500µm, (A’-D’) 100µm. (F) 
Quantification of heart cross-sectional area normalized to body weight. Fgfr1/2
Wt1-Cre
, 
n=10, p<0.003; Fgfr1
Wt1-Cre
, n=5; Fgfr2
Wt1-Cre
, n=9. Control hearts contain Wt1-Cre and 
are a combination of wild type and floxed alleles of Fgfr1 and Fgfr2. Asterisk indicates 
statistically significant difference compared with controls. 
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Figure 4. 
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Figure 4. 
Reduced myocardial, but not epicardial, proliferation in Fgfr1/2
Wt1-Cre
 heart. (A-
B) BrdU incorporation at E15.5. (A’-B’) BrdU incorporation at E17.5. (C) Quantification 
of the percent of BrdU positive cells within the myocardium, showing decreased 
proliferation with age and decreased proliferation in Fgfr1/2
Wt1-Cre
 hearts compared to 
control hearts. E15.5, n=3, * p<0.04; E17.5, n=5, * p<0.03. (D) Quantification of the 
percent of BrdU positive cells within the epicardium showing no difference between 
controls and Fgfr1/2
Wt1-Cre 
hearts. Scale bar: 20µm.  
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Figure 5. 
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Figure 5. 
FGF signaling to epicardial cells regulates migration of EPDCs into the 
myocardium. (A-C) Wt1 immunofluorescence at E17.5 showing fewer Wt1
+
 cells within 
the myocardium of Fgfr1/2
Wt1-Cre
 (B) and Fgf10
-/- 
(C) hearts. Wt1, red; DAPI, blue. (D) 
Quantification of the percent of Wt1
+
 cells in the myocardium. Fgfr1/2
Wt1-Cre
, n=4, * 
p<0.005, Fgf10
-/-
, n=7, * p< 0.03. (E-F) Wt1 immunofluorescence at E17.5 of control (E) 
and Rosa26-rtTA;TetO-Fgf10 (F) induced with doxycycline from E15.5 to E17.5. (G) 
Quantification of the percentage of Wt1
+
 cells in the myocardium. n=5, * p<0.05. (H-K) 
Vimentin immunofluorescence at E17.5 showing fewer vimentin
+
 cells within the 
myocardium of Fgfr1/2
Wt1-Cre
 (I) and Fgf10
-/-
 (J) hearts. Vimentin, green; DAPI, blue. (K) 
Quantification of the percent of Vimentin
+
 cells in the myocardium. Fgfr1/2
Wt1-Cre
, n=8, * 
p<0.005; Fgf10
-/-
, n=10, * p< 0.02. Scale bar in F, I, M, 20μm. White (x) denotes red 
blood cells and dashed white line denotes the epicardial boundary. 
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Figure 6.  
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Figure 6. 
Fgf10 induces migration of EPDCs in explant culture. (A-C) Hearts explanted at 
E17.5 and treated with CFSE for 1 h labels only epicardial cells (A) and not EPDCs that 
have already migrated into the myocardium (B,C). (D-F) pErk immunohistochemistry of 
CFSE-labeled explanted hearts treated with FGF10 (E) and FGF10 plus PD173074 (F) 
for 48 h. Arrows indicates cells positive for pErk and CFSE. (G-J, G’-J’) Migration of 
CFSE-labeled epicardial cells into the myocardium following treatment with FGF9, 
(H,H’); FGF10, (I,I’); and FGF10 plus PD173074, (J,J’). CFSE, green; desmin, red (to 
identify the boundary between myocardium and epicardium), DAPI, blue. (K) 
Quantification of number of CFSE
+ 
within the myocardium after 48 h in culture. +FGF9, 
n=8; +FGF10, n=19, * p<0.003, significant increase compared to control; +FGF10, 
+PD173074, n=10, * p<0.006, significant decrease compared to control.  
(L-N) FGF10-induced CFSE-labeled EPDCs in the myocardium are positive for 
Wt1. Explanted hearts labeled with CFSE were treated with FGF10 (M) or FGF10 plus 
PD173074 (N) for 48 h and then sectioned and immunostained for Wt1. CFSE, green; 
Wt1, red. (O) Quantification of the number of Wt1
+
 cells within the myocardium. FGF10 
treatment significantly increased the number of CFSE
+
,Wt1
+
 double positive cells within 
the myocardium, n=10, * p<0.002; but did not affect the number of pre-existing (CSFE
-
) 
Wt1
+ 
within the myocardium. Treatment with FGF10 and PD173074 significantly 
decreased the number of CFSE
-
,Wt1
+ 
cells within the myocardium, n=10, * p<0.004 and 
the number of CFSE
+
,Wt1
+
 within the myocardium, n=10, * p<0.002. Scale bar: (A-B), 
100µm (D-F, G-J, L-N) 20µm 
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Figure  7.  
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Figure 7. 
Migratory EPDCs become cardiac fibroblasts. Explanted hearts were labeled with 
CFSE and treated with FGF10. After 24 h, hearts were sectioned and stained with 
markers for (A) cardiac muscle, troponin (red); (B) smooth muscle actin, acta2 (red); (C) 
endothelial cells, pecam (red); and (D-F) fibroblasts, vimentin (red). (D’-F’) CFSE is 
only co-expressed with vimentin. Scale bar: 20µm. Dashed squared denotes the 
magnified insert (D’-F’) 
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Figure 8.  
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Figure 8. 
FGF signaling regulates displacement of epicardial cells in culture. (A-D) 
Representative cells and cell paths during the 24 h culture period. (E) Quantification of 
cell displacement over 24 h. (F) Quantification of distance of distance traveled over 24 h. 
Net movement (displacement) of (A’) wildtype and (C’) vehicle treated cells is greater 
than that of Fgfr2b
-/-
 cells, n=79, * p<0.02; and cells treated with PD173074, n=77, ** 
p<0.001. Scale bar: 20µm.  
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Supplemental figure 1.  
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Supplemental figure 1. 
Coronary vasculature in E17.5 hearts. Immunostaining for PECAM/CD31 (red) in 
control, Fgf10
-/- 
and Fgfr1/2
Wt1-Cre
 hearts. (A) Control , (B) Fgf10
-/-
, and (C) Fgfr1/2
Wt1-
Cre
. Compared to controls, the vascular plexus in Fgfr1/2
Wt1-Cre
 and Fgf10
-/-
 hearts appears 
normal. Scale bar: 10µm. Dashed lines contours the epicardial layer. 
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Supplemental figure 2. 
 
 
  
86 
 
Supplemental figure 2. 
Assay for cell death in E17.5 hearts. Immunostaining for activated caspase 3 in 
control, Fgf10
-/- 
and Fgfr1/2
Wt1-Cre
 hearts. (A) Control, (B) Fgf10
-/-
, and (C) Fgfr1/2
Wt1-Cre
. 
No change in capase 3 staining was observed. Scale bar: 20µm. 
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Supplemental figure 3. 
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Supplemental figure 3. 
Identification of EPDCs within the myocardium at E13.5. (A-C) Immunostaining 
for Wt1 (red) showing fewer Wt1
+ 
cells within the myocardium in Fgfr2b
-/-
 (B) and 
Fgf10
-/- 
(C) hearts, compared to control (A) hearts. (D) Quantification of Wt1+ cells 
located within the myocardium. Control, n=5; Fgfr2b
-/-
, n=4, * p< 0.001; Fgf10
-/-
, n=3 ** 
p<0.01. DAPI, blue. White line denotes the boundary between epicardium and 
myocardium and white arrows indicate Wt1
+ 
cells within the myocardium. Scale bar: 
20µm. 
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Supplemental figure 4.  
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Supplemental figure 4.  
EMT is not impaired in Fgfr1/2
Wt1-Cre
 hearts. Immunostaining for E-cadherin 
(green) and β-catenin (red) at E17.5 in control (A) and Fgfr1/2Wt1-Cre hearts (B). Arrows 
indicate points of adhesion of epicardial cells were both E-cadherin and β-catenin are 
normally co-expressed. Immunostaining for Snail1 at E15.5 (bottom) shows normal 
expression in the epicardial cell layer of control and Fgfr1/2
Wt1-Cre
 hearts. Dashed line 
contours the epicardial layer. Scale bar: 10μm.  
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Summary 
 
In this thesis I explored the role of FGF signaling during development of 
epicardial-derived cells (EPDCs). I found that FGF10, secreted from the 
myocardium, signals to FGFR2b in the epicardium to activate migration of epicardial 
cells into the myocardium. Epicardial derived cells populate the heart with vascular 
smooth muscle cells (vsmc) and cardiac fibroblasts (Mikawa and Gourdie, 1996; 
Vrancken Peeters et al., 1999). These cell types are needed in the heart to complete 
the formation of the vascular tree and the fibrous skeleton. I observed that FGF10 
specifically signaled to cardiac fibroblasts but not to vsmc to induce their migration 
into the myocardium. In addition, inactivation of FGF10/FGFR2b/ signaling in 
mouse embryos resulted in a smaller heart visible by embryonic day 17.5 (E17.5). It 
has been shown that cardiac fibroblasts are important for cardiac myocyte 
proliferation during late gestation (Ieda et al., 2009). The largest contributors of 
cardiac fibroblasts during development are  epicardial-derived cells (Krenning et al., 
2010). Therefore, defective migration of cardiac fibroblasts could result in a 
decreased number of cardiac fibroblast within the myocardium, impeding their 
interaction with myocytes. In turn, decreased interaction affects proliferation, leading 
to the formation of a smaller heart. Taking this into account, we hypothesize that 
when the FGF10/FGFR2b/ signaling is disrupted we observe a decrease in heart size 
due to the decrease in cardiac fibroblast migration and subsequent signaling to the 
cardiomyocyte.  
These observations contribute to the knowledge we have about epicardial 
cells. Epicardial cells are important for development and because of their potential to 
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serve as a progenitor cell during cardiac injury. Because developmental pathways 
normally required for the formation of epicardial and epicardial-derived cells may be 
necessary for homeostasis and reactivation of the epicardium in the adult, it remains 
important to learn how to manipulate this cell type in the adult context (Gittenberger-
de Groot et al., 2010; Limana et al., 2010; Shrivastava et al., 2010; Wessels and 
Perez-Pomares, 2004). Therefore, FGF10 could potentially be an important factor 
during heart repair, and future studies are necessary to determine if this is so. Next I 
am going to present various questions that stem from the research done for this thesis 
and discuss potential directions we can take to investigate them.  
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Involvement of FGF7 in epicardial development.  
Fgfr2b
-/-
 hearts have a thinner compact myocardium. FGFR2b is expressed in 
the epicardium, therefore we hypothesized that members of the FGF7 subfamily 
could potentially signal to FGFR2b. To examine this possibility, we performed rt-
PCR of whole wildtype hearts at E17.5. From the members of the FGF7 subfamily of 
ligands, we detected Fgf10 and Fgf7 mRNA expression but not of Fgf3 or Fgf22 
(data not shown). We next examined the overall phenotype of both Fgf10
-/- 
and 
FgF7
-/-
hearts. We found that Fgf7
-/-
 by itself does not develop a smaller heart, but 
Fgf10
-/- 
 does, suggesting that FGF10 is the main ligand for FGFR2b in the 
epicardium. We also were able to generate two Fgf7
-/-
 and Fgf10
-/-
 double germline 
knockouts which yielded an even smaller heart compared to the Fgf10
-/- 
(Figure 1).  
A simple way to explain the differences in the phenotypes of Fgf7
-/-
, Fgf10
-/-
 and the 
Fgf7
-/-
, Fgf10
-/-
, double knockout could be that FGF7 and FGF10 pathways are 
redundant, which leads to a more severe phenotype when both are absent in the 
double knockout. The differences in the severity of the phenotype of the individual 
knockouts could be explained by the different binding specificities of FGF7 and 
FGF10 to FGFR2b in the heart. Binding of FGF ligands to their receptors are 
regulated by heparan sulfate proteoglycans (HSP). HSP epitopes are found to be 
expressed in a tissue-specific and developmentally regulated fashion (Mohammadi et 
al., 2005). It is possible that FGF10, but not FGF7, is favored to bind FGFR2b due to 
the specific HSP present. In this scenario, FGF7 could still bind FGFR2b but not 
predominantly, yielding a very week phenotype when deleted on its own. When 
deleted along with FGF10, the phenotype becomes more severe.  
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In the future, we need to generate more Fgf7 and Fgf10 double knockouts to 
characterize their phenotype and investigate the extent to which Fgf7 is necessary in 
the epicardium for migration of the epicardial cells. It is also possible that deletion of 
Fgf7 along with Fgf10 could uncover other functions of FGF in the development of 
epicardial cells, such as differentiation and EMT that might require a combination of 
both ligands.  
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Initiation and promotion of epicardial cell migration by FGF10 
In studies performed for this thesis, we found that fewer epicardial-derived 
cells, specifically EPDCs that differentiated into cardiac fibroblasts, had migrated 
into the myocardium of Fgfr1/r2
Wt1-Cre 
and Fgf10
-/-
 hearts by late gestational stages. 
In addition, we found that addition of FGF10 to explanted hearts could induce 
migration of labeled epicardial cells into the myocardium. We interpreted that these 
results could reflect either abnormal EMT or migration. We were unable to find 
evidence that EMT was defective in our embryonic mouse models. Instead, we 
observed that wild type isolated epicardial cells move longer net distances than 
Fgfr2b
-/- 
epicardial cells and epicardial cells treated with an FGFR inhibitor. This 
observation suggests that FGF10 can signal to epicardial cells within the epicardial  
layer. It is still unclear if FGF10 acts as a competence factor to potentiate epicardial 
cells to begin migration or if it acts as a signal that is required to direct or promote 
motility during the course of migration. It has been established that FGF10 signals to 
FGFR2b and that when EMT occurs there is a shift in expression from FGFR2b to 
FGFR2c (Savagner et al., 1994). If epicardial cells shifted expression of FGFR2b to 
FGFR2c during EMT, FGF10 could only continue signaling to the EPDCs for as long 
as they retained FGFR2b on their cell surface. In other words, can FGF10 signal to 
epicardial cells and/or the delaminated EPDCs? The simplest way to examine this 
possibility is to determine the dynamic domains of expression of Fgfr2b and Fgfr2c 
in the heart. Unfortunately, no antibody has been developed to specifically detect 
each isoform. One way is to use a general FGFR2 antibody on tissue from individual 
isoform knockouts. Using this method, one can delineate the expression of FGFR2 
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by absence of staining in each specific isoform knockout. Another way to investigate 
if FGF10 could functionally signal to EPDCs is to isolate epicardial-derived cells. 
We know that epicardial-derived cells continue expressing the marker Wt1 as they 
migrate into the myocardium; therefore, cells that are express Wt1 could either be 
epicardial cells or EPDCs (Perez-Pomares et al., 2002; Rhee et al., 2009 ). We also 
know that an adhesion molecule important for long-term attachment of epicardial 
cells is α4β1 integrin; this means that epicardial cells, but not EPDCs, will be 
positive for both α4β1 and Wt1 (Sengbusch et al., 2002). We could use cell sorting to 
isolate epicardial-derived cells based on their being immunopositive for Wt1 and 
immunonegative for α4β1 integrin (Wt1+; α4β1-). Isolated EPDCs from Fgf10-/- and 
wild type hearts can be cultured and visualized using live imaging to calculate the 
net displacement and distance of their movement in the presence of FGF10 protein. 
also, look at ability of different FGF ligands to bind to the cell surfeace ( iodinated or 
fluorescent tagged) 
Whether FGF10 is able to signal to EPDCs as they migrate is important in 
investigating how it elicits that migration. FGF10 could promote migration in various 
ways. FGF10 could act as a chemotactic molecule. It has been shown that FGF10 can 
act as a chemotactic factor for distal lung epithelia; therefore, it is possible that it 
could act in the same way in the heart (Bellusci et al., 1997; Park et al., 1998). Also 
FGF10 could create a gradient of random cell motility without directionality that 
could result in global directed movement (Benazeraf et al., 2010). In addition FGF10 
could signal to the EPDC to maintain establishment of the polarized lamellipodia.  
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In our experiments FGF10 does not appear to be acting as a chemotactic 
factor. In the lung, were FGF signaling is chemotactic, the expression of FGF10 is 
focally located in the mesenchyme. This ensures proper directionality for the 
migration of lung distal epithelium. In contrast, in the heart the expression of FGF10 
appears to be spread throughout the compact myocardium but not focally located. In 
addition, induction of heart explants with FGF10 added to the media; resulted in an 
increased migration of cells into the myocardium when compared with controls. 
These data do not support a chemotactic role for FGF10 in the heart. Nonetheless, we 
have designed experiments to examine directionality of EPDCs. We can isolate 
epicardial cells in colonies, embed them in soft agar, and place a FGF10-coated bead 
in the vicinity of the colony of cells. In the future, we will investigate whether cells 
within these colonies move towards the bead coated with FGF10 or not. We will also 
try isolating colonies of cells from Fgfr2b
-/- 
hearts
 
and treat wild type colonies with 
FGFR inhibitor.  
Our live imaging experiments showed that cells from wildtype, Fgfr2b
-/- 
and 
control cells treated with FGFR inhibitor could all move similar distances, 
suggesting that motility was not impaired by inactivation of FGF signaling in 
epicardial cells. In contrast, only wild type cells treated with vehicle were able to 
show the longest net displacement. This observation implies that Fgfr2b
-/- 
cells and 
wildtype cells treated with inhibitor are able to move as much as controls but that 
their movement is not organized to reach a migratory endpoint. In this experiment 
wildtype epicardial cells did not move in the same direction but were able to move 
successfully from one point to another. In contrast, Fgfr2b
-/- 
cells and wildtype cells 
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treated with inhibitor were not able to move from one point to another, instead they 
remained in the same area. This observation suggests that FGF10 may function to 
create a gradient of random cell motility without directionality that can result in 
global directed movement. 
Interestingly, in the live imaging movies, we observed that wildtype cell were 
able to maintained a polarized lamellipodia, but, Fgfr2b
-/- 
cells and wildtype cells 
treated with inhibitor did not. This observation suggests that FGF10 could control 
migration of EPDCs by the maintenance of a polarized lamellipodia independent 
from directionality. In the future we could investigate this possibility by looking at 
the actin filament organization of Fgfr2b
-/- 
and wildtype cells treated with inhibitor 
during live imaging. In addition we could treat cells with an inhibitor of actin 
filament motor function like blebbistatin (Benazeraf et al., 2010) to observe if it has 
a similar effect to inactivation of FGF signaling.  
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FGF signaling restriction to epicardial-derived cardiac myocytes.  
In our study, we found that the FGF10/FGR2b signaling activates only 
EPDCs that will become cardiac fibroblast, not vsmc, cardiomyocytes or endothelial 
cells. Consistent with this observation, we found a decrease in cardiac fibroblasts 
within the myocardium of Fgfr1/r2
Wt1-Cre
 and Fgf10
-/-
 hearts. This is the first time a 
signal has been identified that specifically targets cardiac fibroblasts versus other 
epicardial-derived cells. In the past, other researchers have reported that PDGFRβ, β-
catenin, Alk5 and Wt1, amongst other genes, are involved in either migration or 
EMT of epicardial-derived cells that specifically develop into vascular smooth 
muscle cells (Martinez-Estrada et al., 2010; Mellgren et al., 2008; Sridurongrit et al., 
2008; Zamora et al., 2007). Mouse models from these genes present two very distinct 
phenotypes of defective EPDC development: poor formation of the coronary 
vasculature due to decreased recruitment or differentiation of vsmcs and thinned 
compact myocardium. In contrast, Fgfr1/r2
Wt1-Cre
 and Fgf10
-/-
 hearts do not display 
problems in the recruitment of vsmc in view of the properly formed vascular plexus. 
Future experiments will concentrate on studying how the FGF signal is restricted to 
only cardiac fibroblasts. Possible mechanisms of specificity could entail a balance 
between PDGFβ signaling and FGF signaling. For example, epicardial cells could 
receive both signals but only able to interpret and respond to one. In this case , many 
other genes could be involved in making the epicardial cell competent to receive or 
suppress one or the other signal. Other genes like Sprouty or Cbl which modulate 
downstream pathways or recycling of receptor tyrosine kinases (RTKs) could also 
play a role (Aranda et al., 2008; Miyake et al., 1999). Another plausible mechanism 
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is timing, for example PDGFβ signaling could occur prior or after FGF signals to 
epicardial cells. Alternatively, all epicardial cells may be fated to become vsmc, but 
activation of FGF10/FGFR2b signaling results in differentiation into cardiac 
fibroblasts, or vise versa. 
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Indirect induction of cardiomyocyte proliferation through the cardiac fibroblast 
Our study provides evidence that migration of cardiac fibroblast into the 
myocardium plays a role in cardiomyocyte proliferation. We observed a decrease in 
proliferation of cells within the myocardium in Fgfr1/r2
Wt1-Cre
 and Fgf10
-/- 
hearts that 
result in a smaller heart, visible at late gestation. There are a couple of ways that 
FGF10/FGFR2b signaling could regulate proliferation. One is by signaling to the 
FGF9/FGFR1c/FGFR2c pathway during midgestation or by inducing other factors 
made in the epicardium. Another possible way is by inducing migration of cardiac 
fibroblast during ventricular compaction (Ieda et al., 2009; Lavine et al., 2005). The 
FGF9/FGFR1c/FGFR2c pathway has been established as the main mechanism for 
cardiac myocyte expansion after heart looping and throughout midgestation.  In this 
pathway, retinoic acid receptor promotes expression of FGF9 and FGF16 in the 
epicardium and endocardium. FGF9 and FGF16 signal to FGFR1c and FGFR2c in 
the myocardium to directly activate proliferation and inhibit differentiation. This 
pathway indirectly induces SHH expression in the epicardium which results in the 
activation of VEGF and ANG2. VEGF and ANG2 promote formation of the vascular 
plexus. Originally we thought that FGF10 signaling to FGFR2b might function in a 
reciprocal feedback loop with FGF9/FGFR1c/FGFR2c to ensure sustained signaling 
to cardiomyocytes and induction of SHH during midgestation. When we examined 
development of the primitive vascular plexus, we found no delay in its formation. 
We hypothesized that if the reciprocal signal was abrogated in Fgfr1/r2
Wt1-Cre
 and 
Fgf10
-/- 
 hearts we would see changes in the expression of FGF9. In the future, we 
need to examine the expression of FGF9 in these mouse models to find out if FGF9 
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is regulated. Correspondingly, we did not observe any changes in heart size in 
Fgfr1/r2
Wt1-Cre
 and Fgf10
-/-
 embryos at midgestation when the 
FGF9/FGFR1c/FGFR2c signaling is active. Instead, we observed changes in heart 
size at late gestation starting at E17.5 coincident with the time of ventricular 
compaction. Our proliferation analysis revealed that proliferation was decreased at 
E15.5 and E17.5 in Fgfr1/r2
Wt1-Cre
 and Fgf10
-/-
 hearts. Taken together, these data 
suggest that FGF10/FGFR2b signaling pathways do not have a function along with 
the mechanism of cardiomyocyte proliferation during midgestation. The data points 
to a function of FGF10/FGFR2b in the later stages of cardiomyocyte expansion.     
  Recently it has been acknowledged that embryonic cardiac fibroblasts are 
important to promote β1-integrin activated-proliferation of cardiac myocytes by 
secretion of HBEGF. β1-integrin can induce activation of PI3k/Akt and 
MEK/ERK1/2 in cardiomyocytes and promote cell division. This has been regarded 
as the mechanism of heart growth during endpoint heart development. The main 
source of embryonic cardiac fibroblasts is thought to arise from the epicardial -
derived cell. Other studies also have implicated not only differentiated cardiac 
myocytes but also EPDCs as a cell type that can physically interact with cardiac 
myocytes to induce cell proliferation, cellular alignment and contraction (Eid et al., 
1992; Weeke-Klimp et al., 2010) .   
We hypothesize that in the absence of proper EPDC migration, fewer 
epicardial-derived fibroblasts are going to invade the myocardium. This will result in 
a decrease of β1-integrin- activated cardiomyocyte proliferation and lead to the 
formation of a smaller heart. The phenotype of the Fgfr1/r2
Wt1-Cre
 and Fgf10
-/-
 is 
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consistent with this hypothesis. In Fgfr1/r2
Wt1-Cre
 and Fgf10
-/-
 hearts, we observed a 
decrease in the migration of cardiac fibroblasts. Furthermore, we observed decreased 
proliferation of cardiac myocytes. We hypothesize that as a result of decreased 
epicardial-derived fibroblasts, migration β1-integrin signaling in the cardiac 
myocytes of Fgfr1/r2
Wt1-Cre
 and Fgf10
-/-
 hearts is impaired. In the future, we need to 
explore this hypothesis. The downstream pathways controlling β1-integrin cell 
division are PI3k/Akt and MEK/Erk1/2. A simple way to evaluate the activation of 
these downstream pathways is to compare the expression of Akt and/or Erk1/2 in 
Fgfr1/r2
Wt1-Cre
 and Fgf10
-/-
 hearts with controls. A more functional approach would 
be to co-culture isolated cardiac fibroblasts from Fgfr1/r2
Wt1-Cre
, Fgf10
-/-
 and controls 
with isolated cardiac myocytes and ask whether proliferation of cardiomyocytes is 
decreased in the mouse models. It is already known that increased titration of 
isolated embryonic cardiac fibroblasts in co-cultures with myocytes increases 
proliferation of cardiac myocytes; therefore, we will only see a difference using this 
approach if we originally isolate fewer cardiac fibroblasts from Fgfr1/r2
Wt1-Cre
 and 
Fgf10
-/-
 compared to control hearts. On the other hand, if we isolate similar amounts 
of cardiac fibroblast from Fgfr1/r2
Wt1-Cre
, Fgf10
-/-
 and controls and see no difference 
in proliferation, it could mean that cardiac fibroblasts from Fgfr1/r2
Wt1-Cre
 and Fgf10
-
/-
 are unable to signal. In this case, we could look at the ability of these cells to 
induce β1-integrin-activated proliferation through the growth factor HBEGF. We 
also could explore the ability of the cardiac myocytes to produce Fibronectin1 and 
Collagen 3, two ECM proteins known to bind β1-integrin to induce cardiomyocyte 
proliferation.   
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FGF10/FGFR2b in adult heart repair 
The study of heart repair is important for the development of therapies that 
could help treat heart disease, one of the most prevalent causes of mortality 
worldwide. One important area of investigation is the repair of damaged tissue due to 
myocardial infarction. Competent cardiac healing requires the proliferation of 
myocytes, formation of new vessels and regulation of vascular remodeling. One of 
the approaches taken in the past is reperfusion with known cardioprotective and 
angiogenic factors like VEGF and FGF2 (Molin and Post, 2007). The expectation is 
that these cardioprotective molecules will cause proliferation of cardiomyocytes, 
vascularization and reduction of the fibrotic response. Although these approaches 
have been successful in isolated ischemic heart models and transgenic mouse models, 
they have been disappointing in clinical trials (Ludman et al., 2010). Failure of these 
approaches seems to stem from the quantity and sustainability of the growth factor 
and the targeting and delivery of the cells.  
Another approach undertaken in the field is the use of cardiac progenitor 
cells. These cells are typically grafted into the injured heart with the expectation that 
it will divide and generate progeny to supply the healing myocardium (Di Nardo et 
al., 2010). If developed properly, this method could overcome the targeting and 
dosage problems found with angiogenic therapies, but it could be challenging to 
bypass the surveillance of the immune system for rejection. In the past , several stem 
cell types have been studied, such as the cardiac progenitor cell and the 
mesenchymal stem cells, with some success of protection to the injured mouse and 
rat heart. (Christoforou et al., 2010; Jin et al., 2009; Yi et al., 2009).  
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Recently this approach has been used to study the effects of epicardial cells in 
the injured heart. Epicardial cells are considered to be undifferentiated cardiac 
progenitor cells (Wessels and Perez-Pomares, 2004). These cells have been found to 
differentiate into vascular smooth muscle cells, interstitial fibroblasts and 
cardiomyocytes, although the latter is still controversial. Recently a study isolated 
epicardial cells from adult human hearts, labeled them and injected into a mouse 
heart (myocardial infarct) MI model. This injection resulted in increased 
vascularization, cardiac function and decreased remodeling, suggesting that adult 
epicardial cells are able to promote cardiac protection (Winter et al., 2007). In this 
study, epicardial cells did not differentiate into cardiomyocytes, but engrafted rapidly 
in the heart suggesting that factors secreted by the epicardial cells could be important 
for cardioprotection. Additionally, Thymosin β4 has been shown to promote 
epicardial cell migration that results in differentiation to vsmc and endothelial cells 
in the adult mouse MI models (Smart et al., 2010).  
In our studies, we observed that FGF10/FGFR2b signaling can induce 
migration of epicardial cells in vivo and in vitro. In the future, it would be important 
to investigate whether administration of FGF10 in the adult injured mouse heart can 
elicit similar cardioprotective effects to Thymosin β4. Many experiments could be 
designed to examine the role of FGF10 in repair. First, it would be important to see if 
FGF10 can elicit migration of adult epicardial cells in pathological and 
pathophysiological conditions. We could generate adult mice bearing GFP-labeled 
epicardial cells by crossing Gata5Cre with a R26R-EGFP reporter mouse. FGF10 
could be administered either locally or systemically, and epicardial cells of Gata5-
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EGFP hearts could be monitored for migration and differentiation. In parallel, we 
could use FGF10-inducible mice (Rosa26-rtTA, TetO-Fgf10) to promote FGF10 
expression in the adult. To follow epicardial cells, we could inject very low doses of 
CFSE into the pericardium of the heart. If migration of adult epicardial cells was 
successfully activated using any of these two approaches, we would expect to see an 
increase in cardiac myocyte proliferation. We also expect FGF10 to promote 
epicardial cell migration; specifically of cardiac fibroblasts, but not vsmc or 
endothelial cells. The effects of treatment with FGF10 could differ from Thymosin 
β4. Thymosin β4 is known to induce vascularization but not proliferation of 
cardiomyocytes. Next we could repeat the same experiments using the adult MI 
model heart to uncover the response of epicardial cells to FGF10 during repair.   
If adult epicardial cells are unable to respond to FGF10 we could examine the role of 
embryonic epicardial cell grafts pre-treated with FGF10 in the adult. For these 
experiments, we could isolate embryonic epicardial cells, label them with CFSE and 
treat them with FGF10. We can inject labeled-induced cells into adult infarcted 
mouse hearts and monitor the role of these cells in myocardial repair.     
In summary, FGF10 signaling to FGFR2b in epicardial cells is one of the first 
signaling pathways found to be required for epicardial cell migration. I t is very 
important to examine and study the potential of this pathway to indirectly affect 
myocyte proliferation. Understanding of this pathway and the pathways it interacts 
with will aid in formulating a more comprehensive view of heart development. 
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Figure 1.  
 
 H&E staining of double knockout of FGF7
-/- 
; FGF10
-/-
. (A) H&E of control. (B) 
H&E of Fgf10
-/- 
. (C) H&E of FGF7
-/- 
; FGF10
-/-
. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Appendix A 
Role of TGFβ in coronary vascular formation 
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Abstract 
 
We have shown that initiation of vessel tube formation during 
coronary vascular development requires the expression of VEGF ligands and 
receptors. We know that induction of VEGF expression is regulated by a 
FGF9/FGFR1c/FGFR2c pathway that leads to the indirect activation of SHH. 
In turn, SHH induces expression of VEGF through Patched 1 activation in the 
myocardium. Here we explore alternative mechanisms of VEGF activation. In 
Fgfr1/r2
Mlc2v-Cre
 embryos, coronary artery formation is only delayed, 
therefore, we hypothesized that other RTKs could be part of the normal 
VEGF activation and that these elicit a compensatory mechanism observed in 
the Fgfr1/r2
Mlc2v-Cre 
mouse model. Alternatively we hypothesized that other 
transcription factors could directly regulate expression of VEGF independent 
from SHH signaling. In this study we look at TGFβ signaling as a candidate 
pathway to induce VEGF expression during coronary vascular formation. 
TGFβ signaling could act in a compensatory mechanism by inducing SHH in 
a synergistic manner with FGF. Alternatively TGFβ could directly regulate 
expression of VEGF. We failed to find evidence that would implica te TGFβ 
signaling as important to regulate VEGF expression and in turn vascular 
formation.  
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Introduction 
 
One of four Americans suffers from some sort of heart disease. Elucidating 
the different molecular cascades which interplay to form the cardiovascular system 
can lead to a better understanding of adult heart injury and healing.  FGF’s, SHH, 
VEGF’s and TGFβ’s are molecules that have been shown or proposed to be 
important in myocardial proliferation and vasculogenesis. In this investigation we 
evaluate the possibility that TGFβ could act downstream or synergistically during 
FGF induced coronary vascular formation. We also look at the role of TGFβ in 
coronary vascular development by deleting Tgfβr2 in the myocardium.   
 
The Transforming Growth Factor Beta Super Family can be divided in two 
sub groups, the Activin receptor response members and the Bone Morphogenetic 
Protein (BMP) receptor response members (Moustakas and Heldin, 2009). Secreted 
ligands from both groups signal through distinctive type I (signal transducing) and 
type II (ligand binding) serine/threonine receptor complexes (Mokrosinski and 
Krajewska, 2008). This signal is transduced intracellularly by the Smad family of 
transcription factors. Smads are classified as, receptor regulated Smads (R-Smads), 
common mediator Smad (Co-Smad) and Inhibitor Smad (I-Smads). The R-Smads are 
activated through the receptor, consequently heterodimerizes with Co-Smad and 
enter the nucleus where they can form transcriptional complexes (Miyazawa et al., 
2002).  
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TGFβ super family has been found to have an important function during heart 
development. The role of TGFβ isoforms during heart development is not clearly 
understood. Not much is known about the TGFβ3 although it is present in the 
epicardium along with TGFβ1 and TGFβ2. TGFβ2 deficient mice have defects in 
valve development and septation. In addition data suggest that ALK5 play a role in 
heart looping (Sanford et al., 1997).  TGFβ1, 2 and 3 are reported to be 
immunolocalized in all tissues of the heart. TGFβ2 being the most prominent in 
cardiomyocytes is also localized at the media and adventitia layer of the blood 
vessels and in the outflow track (OFT) of the heart. TGFβ1 is expressed in the 
endocardial layer and TGFβ3 is expressed in the cardiac cushions and cardiac 
fibroblasts (Molin et al., 2003). TGFβ signaling has been implicated in epithelial to 
mesenchymal transition not only of the cardiac cushion but also of epicardial derived 
cells but it is not yet clear whether it stimulates or inhibits EMT of epicardial derived 
cells . Studies from different laboratories are contradictory. In the chicken embryo 
addition of TGFβ2 and TGFβ3 inhibit EMT in epicardial monolayers. This contrasts 
with previous reports that showed treatment with TGFβ3 to chicken explanted hearts 
induced EMT. Although debatable, most reports suggest TGFβ signaling can induce 
EMT (Compton et al., 2006; Dokic and Dettman, 2006; Morabito et al., 2001). 
 
VEGF ligands and receptors are important during coronary vasculogenesis. 
Induction of VEGF expression is controled by a FGF9/FGFR1c/FGFR2c pathway 
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that leads to the indirect activation of SHH. SHH expressed in the epicardium 
induces expression of VEGF in the myocardium signaling to its receptor Patched1. 
Induction of VEGF signaling by FGF is not completely abrogated, therefore, we 
hypothesized that other RTKs could be part of the normal VEGF activation and that 
these could elicit a compensatory mechanism observed in the Fgfr1/r2
Mlc2v-Cre 
mouse 
model. Another possibility is that RTK’s could directly regulate expression of 
VEGF, independent of SHH signaling. In this study we explored TGFβ signaling as a 
candidate signaling pathway to induce VEGF expression during coronary vascular 
formation. TGFβ signaling could be one compensatory pathway by which VEGF 
activation is induced along with FGF. Alternatively, TGFβ could directly regulate 
expression of VEGF through it downstream effectors Smad2/3.  
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Results 
 
In Fgfr1/r2
Mlc2v-Cre
 embryonic hearts, the vascular plexus basal to apical 
migration is delayed. This delay is attributed to a decrease in VEGF expression in 
knockout hearts. We hypothesize that TGFβ signaling could be increased in 
Fgfr1/r2
Mlc2v-Cre
 embryonic hearts as a compensatory mechanism to induced VEGF 
expression and in turn vascular tube formation. In order to examine this hypothesis 
we performed western blots of control and Fgfr1/r2
Mlc2v-Cre
 hearts to look at the 
expression of activated Smad 2/3 the transcription factors downstream of TGFβ 
signaling normalized to endogenous Smad2/3 at E12.5 and E13.5 (Figure 1A-1B). 
We quantified the amount of protein but we were unable to detect any differences 
between controls and Fgfr1/r2
Mlc2v-Cre
 hearts suggesting that TGFβ does not act as a 
compensatory mechanism to assure the proper formation of the primitive vascular 
plexus (Figure 1C.)  
Next we hypothesize that TGFβ signaling could directly regulate the 
expression of VEGF by the binding of Smad2/3 to VEGF regulatory sequences.  We 
observed that various VEGF ligands are expressed in a similar spatio temporal 
manner during coronary heart development.  vegf-b and vegf-c are expressed in the 
same gradient fashion as previously describe for vegf-a. This concerted spatio-
temporal expression suggests that all three ligands could be co-regulated during 
vasculogenesis. To look at known regulatory motifs that could explain these gene 
expression patterns, we used the program Promoter Analysis Pipeline. With this 
program you can examine the coincidence of binding sites of known transcription 
factors between possible co-regulated genes. We analyzed the promoter regions of 
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vegf-a, vegf-b and vegf-c and observed that they shared conserved and non-conserved 
Smad2 binding motifs (Figure2A-2C). This finding suggested that TGFβ signaling is 
capable of regulating VEGF ligand expression in a coordinated manner.  
 
To test if Smads could control VEGF expression directly by binding to VEGF 
ligand regulatory sequences we created a myocardial deletion of Tgfβr2. TGFβR2 
binds all three TGFβ ligands and is necessary to phosphorylate the receptor type I 
complex. We hypothesize that TGFβ ligands expressed in endocardium, epicardium 
and/or myocardium could bind TGFβR2 in cardiac myocytes and elicit the activation 
of Smad2/3 in myocardial cells. Smad2/3 in turn could directly bind to VEGF 
sequences in cardiac myocytes. Binding of Smad2/3 could induce VEGF expression 
in cardiac myocytes and VEGF ligands emanating from cardiac myocytes could 
activate VEGF receptors localized at endothelial cells to induce endothelial tube 
formation. To test this hypothesis, we stained controls and Tgfβr2Mlc2v-Cre from E12.5 
and E13.5 with Pecam, a marker for endothelial cells that marks the primitive 
vascular plexus. We observed no change in the density or rate of vascular formation 
in Tgfβr2Mlc2v-Cre compared to control hearts (Figure 3). 
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Discussion 
 
Our laboratory has demonstrated that FGF signaling promotes proliferation of 
the cardiomyoblast cell population and coronary vascular development (Lavine et al., 
2005). FGF9 and FGF16 signal to FGFR1 and FGFR2 in the myocardium to induce 
proliferation and simultaneously promoting SHH activity. SHH signaling directly 
regulates VEGF and in turn coronary vascular formation (Lavine and Ornitz, 2008). 
In the Fgfr1/r2
Mlc2v-Cre 
mouse model, the delay in vascular development is moderate 
suggesting that other growth factors might play a role in vasculogenesis. TGFβ has 
been proposed to be an angiogenic factor and a regulator of FGF signal in vitro, but 
there is a lack of data to link TGFβ to coronary vascular formation (Hildner et al., 
2010).  
 
Here we tried to find evidence that TGFβ could have a role in coronary 
vascular formation through interaction with FGF signaling by either a compensatory 
mechanism or a synergistic mechanism. It has been reported that FGF and TGFβ 
have both opposing and combinatorial effects in different biological processes 
(Bosse et al., 2006; Ko et al., 2009; Lee et al., 2010; Ramos et al., 2010). We were 
unable to observe a differential expression of TGFβ upon deletion of FGF receptors 
in the myocardium, suggesting that TGFβ is unlikely to compensate for the lack of 
FGF signaling during midgestation. One possible explanation is that many other 
receptor tyrosine kinases are recruited to ensure proper growth and formation of the 
coronary vasculature. This could be a mechanism of heart development to protect 
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organ survival via a compilation of redundant pathways. Other possible RTK’s 
involved in myocardial growth are IGF2, Erb and PDGF signaling.  
 
The observation that TGFβ is unchanged upon FGF signaling ablation does 
not eliminate the possibility that TGFβ signaling could control vessel development 
directly in cardiac fibroblasts. Although all three VEGF ligands have binding 
sequences for Smad in their promoter region we did not observed any defect in the 
formation of the vasculature, suggesting that VEGF ligands are able to signal 
properly in the absence of TGFβ signaling from the cardiomyocytes. This result 
suggests that TGFβ signaling is dispensable in the cardiac myocyte because no other 
growth or morphological defects were observed. Consistent with this observation 
deletion of Alk5 (a TGFβ type I receptor) in the myocardium results in no phenotype 
(Sridurongrit et al., 2008).   Alternatively, TGFβ action could be necessary in other 
cell type of the heart during coronary vascular formation. TGFβ ligands are 
expressed in many other cell types such as the epicardium, endocardium, cushion 
mesenchyme, cardiac fibroblast and smooth muscle cells, and endothelial cells. 
Elucidating which cell type requires the activation of TGFβ will require conditional 
inactivation of these genes. Another possibility is that another TGFβ receptor type II 
could be acting redundantly within the cardiac myocyte.  
 
To conclude, we found that FGF signaling does not interact with TGFβ to 
contribute to formation of the coronary vasculature and that TGFβ signaling in the 
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myocardium is dispensable for coronary vascular development. This conclusion is 
consistent with published results were deletion of Alk5 (a receptor type 1) in the 
myocardium does not play a major role in the myocardium during development. 
Taken together this information supports that TGFβ signaling in the myocardium is 
not necessary for heart development (Sridurongrit et al., 2008). 
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 Materials and Methods 
 
Western blot 
  Homogenize heart in RIPA buffer with protease inhibitor cocktail. Measure 
protein concentration using Bradford test and boil sample for 5min at 95°C. Run gel 
using precast biorad gels and Biorad running gel buffer. Transfer 1h and 30min at 80 
volts at 4°C. Block for 1h with 5% powder milk at 4°C. Primary antibody (Santa 
Cruz Biotechnologies, sc-11769) 1h. Incubate in secondary antibody for 1h. Develop 
using luminescent reagent. Strip and reprobe.  
 
Promoter analysis pipeline (PAP) 
Is a software developed by the Washington University Biomedical 
Informatics Core. The software analyzes a set of co-expressed genes (in this case 
VEGF ligands co-expressed in the heart) to identify possible transcription factor that 
could be orchestrating their co-expression in vivo. The software identifies shared 
transcription factor motifs that are found in the promoter region of the genes of 
interest. To use this software you create an account in the following website  
http://bioinformatics.wustl.edu/webTools/PromoterAnalysis.do;jsessionid=2D5029F
D0BAF20BC7E82F452B8CD97CD 
Once created you are able to input the accession numbers of your genes of interest. 
The software runs remotely so you do not have to download the program. The results 
are displayed with an option to export them to your personal files.  
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Whole mount immunohistochemistry of pecam 
Tissue is fixed in 4%PFA overnight at 4°C. Tissue is dehydrated in methanol 
series and block from endogenous peroxidase using 4 to1 volumes of methanol to 
30% hydrogen peroxide for 3h. Tissue is rehydrated in methanol series. Tissue is 
incubated with ProteinaseK 10μg/ml for 30 min at room temperature. Block with 2% 
skim milk, 5% serum, 0.1%BSA, 0.1%triton-x for 2h. Primary (Abcam, ab28364) 
antibody in blocking overnight. Secondary antibody byotinilated. Develop in DAB.  
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Figures and Figure Legends 
Figure 1. 
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Figure 1. 
Western blot for Smad2/3 and pSmad2/3 at embryonic stages E12.5 and 
E13.5. (A) Shows the expression of Smad2/3 (top row) and pSmad2/3 (bottom row) 
of control and Fgfr1/r2
Wt1-Cre 
knockout hearts. Expression of Fgfr1/r2
Wt1-Cre 
is similar 
to controls in both the endogenous Smad2/3 and pSmad2/3 at E12.5. (B) Shows the 
expression of Smad2/3 (top row) and pSmad2/3 (bottom row) of control and 
Fgfr1/r2
Wt1-Cre 
knockout hearts. Expression of Fgfr1/r2
Wt1-Cre 
is similar to controls in 
both the endogenous Smad2/3 and pSmad2/3 at E13.5. HepG cells were used as 
negative control. Positive control was obtained by inducing HepG cells with TGFβ3 
protein to induce Smad phosphorilation. (C) Quantification of optical density for 
western blots resulted in no change once normalized to endogenous levels of 
Smad2/3. Controls and Fgfr1/r2
Wt1-Cre +
 n=4. 
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Figure 2. 
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Figure 2.   
Shared promoter sites for Smad3 in vegf-a, vegf-b and vegf-c. (A) Shows 
conserved and non conserved Smad3 transcription binding site on (hs) human and 
(Mm) mouse for vegf-a. (B) Shows conserved and non conserved Smad3 
transcription binding site on (hs) human and (Mm) mouse for vegf-b. (C) Shows 
conserved and non conserved Smad3 transcription binding site on (hs) human and 
(Mm) mouse for vegf-c 
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Figure 3. 
 
 
 
136 
 
Figure 3. 
Whole mount pecam immunohistochemistry. (A-A’) Tgfβf/+, n=3 , E12.5 and 
E13.5 respectively . (B-B’)  Tgfβf/f (C-C’) E12.5 and E13.5 respectively.  n=3  
Tgfβr2Mlc2v-Cre n=3 E12.5 and E13.5 respectively. Scale: 500μm 
 
 
 
 
 
  
 
 
 
 
 
Appendix B 
Inactivation of Fgfr1 and Fgfr2 using the epicardial specific Gata5-Cre does not 
affect, epicardial development or coronary vascular formation during midgestation 
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Abstract 
Previously we found that deletion of Fgfr2b in the germline leads to decrease 
cardiomyocyte proliferation and as a smaller heart. Germline inactivation causes 
deletion of Fgfr2b in all the cells of the mouse embryo, therefore we cannot 
distinguish in which cell type is the action of Fgfr2b required. We hypothesized that 
Fgfr2b and or Fgfr1b could be functioning in the epicardial layer of the heart. Here 
we deleted Fgfr2b and Fgfr1b specifically from the epicardium using Gata5-Cre. We 
found that unlike deleting Fgfr1 and Fgfr2 with another epicardial Cre (Wt1-Cre) or 
deleting Fgfr2b in the germline deletion of Fgfr2b and Fgfr1b
 
during the spatio-
temporal context of Gata5-Cre activation is dispensable for heart development. 
Differences in the effect of Fgfr2b
-/- 
and Fgfr1/r2
Wt1-Cre 
in heart development vs 
Fgfr1/r2
Gata5-Cre
 could be due to various reasons: for example, target of cell type 
within the epicardium, effective cre recombination and temporal expression of the 
Cre-line.  
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Introduction 
 The epicardium is the outermost layer of the heart. Epicardial cells travel 
from the proepicardium to the posterior base of the heart and migrate and extend 
over the heart as a single cell layer. Later they undergo epicardial to mesenchymal 
transitions to give rise to vascular smooth muscle cells (vsmc), cardiac fibroblasts 
and pericytes (Cai et al., 2008; Dettman et al., 1998; Merki et al., 2005; Mikawa and 
Fischman, 1992; Mikawa and Gourdie, 1996; Snider et al., 2009). These cells are 
very important to the formation of the adult heart. Vascular smooth muscle cells 
become part of the arterial wall and cardiac fibroblasts interact with myocytes to 
induce proliferation (Kattan et al., 2004; Lavine et al., 2006; Red-Horse et al., 2010). 
Epicardial differentiation is not well understood, it is hypothesized that these cells 
express different cell fate markers as early as in the proepicardium. In addition, how 
these cells migrate into the myocardium is not very well studied either. 
FGF signaling is very important during development. The FGF family is 
composed of fifteen canonical ligands and four receptors (Itoh and Ornitz, 2008; 
Ornitz and Itoh, 2001; Turner and Grose, 2010). FGFR1, FGFR2 and FGFR3, but not 
FGFR4, undergo alternative splicing and give rise to alternative splice variants c and 
b. FGFR splice variant b is consistently expressed in epithelial like tissues and FGFR 
splice variant c is preferentially expressed in mesenchymal like tissue. The ligands 
are classified in subgroups due to their sequence similarity and ligands within a 
group activate the same receptor splice variant with similar affinity (Itoh and Ornitz, 
2004). FGF signal transduction can proceed through the activation of three main 
140 
 
pathways: Ras/MAPK pathway, phospholipase Cγ (PLCγ)/Ca2+ pathway, and the PI3 
kinase/Akt pathway (Eswarakumar et al., 2005; Lemmon and Schlessinger, 2010). 
FGF signaling has been shown to be important during heart development. FGF9 
emanating from the epicardium signals to receptors FGFR1c and FGFR2c in the 
myocardium to induce cardiomyocyte proliferation (Lavine et al., 2005). In addition 
FGFR2b, which is tought to be expressed in the epithelial cell types of the heart,  is 
also important for the control of heart size. The main epithelial cell types and 
epithelial-like cell types of the heart are endothelial cells, endocardial cells and 
epicardial cells (Marguerie et al., 2006). We have deleted FGFR1 and FGFR2 using 
two endothelial specific Cre alleles (Tie2-Cre and Flk1-Cre) and found that both 
animal models to undergo normal heart development. Hence, we hypothesized that 
FGFR2b could function in epicardial cells. To test this hypothesis we used Cre-Loxp 
recombination to inactivate Fgfr2b in the epicardium using an epicardial specific Cre 
(Gata5-Cre) that we refer to here as Fgfr1/r2
Gata5-Cre
. We found that Fgfr1/r2
Gata5-Cre
 
hearts do not develop a smaller heart, in addition we found that the coronary 
vasculature in these hearts is normal. This suggests that FGFR1b and FGR2b in the 
epicardium do not exert a function during the spatial and temporal domain of Gata5 
expression. Alternatively, recombination by Gata5-Cre could be innefficient or 
restricted to a non-fibroblast lineage.  
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Results 
To determine if Gata5-Cre would induce recombination in the epicardial 
layer, we crossed Gata5-Cre mice with the Rosa26 reporter mice (hereafter refer as 
Rosa26;Gata5-Cre). We then examined if recombination led to expression of β-
galactosidase in the epicardium (Figure 1). We observed that expression of β-
galactosidase was present in Rosa26;Gata5-Cre but not in control littermates lacking 
either or both: Gata5-Cre and or Rosa26. The expression of β-galactosidase in the 
epicardium suggested that Gata5-Cre is able to induce recombination in epicardial 
cells. 
 We then created the Fgfr1/r2
Gata5-Cre
 mice and looked at the general histology 
by H&E staining (Figure 2).  The H&E showed that at E13.5 Fgfr1/r2
Gata5-Cre
 
embryonic hearts seemed to have less subepicardial space but the thickness of the 
compact myocardium was comparable to control littermates. Decrease subepicardial 
mesenchyme could result in defects in epicardial EMT, migration and differentiation. 
Disruption of these processes can lead to defects in coronary vascular formation 
because epicardial derived cells contribute to the media layer of coronary arteries.  
We hypothesize that deletion of Fgfr1 and Fgfr2 with Gata5-Cre could lead to 
improper formation of the coronary vasculature. We examined the endothelial 
vascular plexus of controls and Fgfr1/r2
Gata5-Cre
 hearts and found that coronary artery 
formation proceeds normal at E13.5 (Figure 3). We looked at the formation of 
subepicardial vessels and intramyocardial vessels and found that both are present in 
controls and Fgfr1/r2
Gata5-Cre
 hearts (Figure 3A’-3B’). We next followed the growth 
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of these heart at later stages and found that both, their size and coronary vessel 
development is normal (Figure 3C-3D).  
We measured the relative area of controls and Fgfr1/r2
Gata5-Cre
 at E13.5 and 
E17.5 and found no significant difference between them (Figure 3E). We next 
wanted to see if the apparent decrease in subepicardial mesenchyme, observed in 
Fgfr1/r2
Gata5-Cre 
hearts
 
would lead to defects in EMT. We looked at two main EMT 
markers, cytokeratin and vimentin (Figure 4). When cells are undergoing EMT they 
shift their cytoskeleton from epithelial-like (cytokeratin) to mesenchymal –like 
(vimentin). We observed no difference between controls and Fgfr1/r2
Gata5-Cre
 hearts 
in their expression of cytokeratin in the epicardial layer or vimentin within the 
myocardial area. We measured the relative pixel intensity (mgv) of the cytokeratin 
expression in the epicardium and failed to find any significant change between 
littermate controls and Fgfr1/r2
Gata5-Cre
hearts. Next, we checked Wt1 expression 
because this gene has been shown to induce epicardial to mesenchymal transition 
(Figure 5). We measured the total number of Wt1
+ 
cells within the epicardium, sub 
epicardium and myocardium and found no difference in the total number of Wt1
+
 
cells when compared to controls  and  Fgfr1/r2
Gata5-Cre+ 
embryonic hearts. 
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Discussion  
We expected that ablation of Fgfr1 and Fgfr2 in the epicardium with Gata5-Cre 
would lead to a smaller heart similar to Fgfr2b
-/- 
phenotype, but failed to detect any 
differences between controls and Fgfr1/r2
Gata5-Cre
 hearts. This result is surprising 
because it differs from the results we observed in chapter two of this thesis using the 
Wt1-Cre allele. Using Wt-1Cre, we observed a very similar phenotype to the Fgfr2b
-
/-
 mouse. We propose that these differences could be due to the following reasons:  
1. The time of expression of Gata5-Cre. The germline knockout of Fgfr2b is deleted 
throughout development, therefore, the function of FGFR2 is abrogated at all time 
points in development. On the other hand Gata5-Cre starts to be expressed at 
E9.25 in proepicardial cells and continues to be expressed in the epicardial cell. 
Alternatively, Wt1-Cre expression starts in the proepicardium at E9.5 and 
continues to be expressed in the epicardium all throughout development, similar 
to Gata5-Cre. These differences in timing of ablation could lead to different 
phenotypic results. 
 
2. The cell type that expresses Gata5-Cre. The germline knockout targets every 
single cell in the mouse embryo but Gata5-Cre only targets the proepicardial and 
epicardial cells but not the epicardial derived cells. In contrast Wt1-Cre continues 
its expression in epicardial derived cells making it not only an epicardial deletion 
but also an epicardial derived cell deletion of FGFR1 and FGFR2. These 
differences could account for the discrepancy in the phenotypes.  
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3. The type of Cre. Gata5-Cre is a transgenic Cre insertion but Wt1-Cre is a knock-
in of Wt1 sequences driving cre recombinase cDNA inserted at the Wt1 gene 
locus. This insertion results in the expression of just on normal allele of Wt1. It is 
possible that haploinsufficiency of Wt1 could create a more sensitive genetic 
background and result in the different phenotypes we described here and in 
chapter two. However, alone, Wt1-Cre does not affect EPDC migration into the 
myocardium. 
 
4. Background of mouse strains. Although both Gata5-Cre and Wt1-Cre have been 
mated into mix backgrounds there still a possibility that the genetic makeup of the 
lines is different and susceptibility mutations could be generating the contrasting 
phenotypes.  
 
5. The phenotype in Gata5-Cre might not be as severe. The phenotype could still be 
present in Fgfr1/r2
Gata5-Cre
 hearts but differences like the ones mentioned: mouse 
strain,  timing and temporal expression could be responsible for a less severe 
phenotype that we don’t have the sensitivity to detect.   
 
6. In addition, the effectiveness of Cre recombination could be compromised in 
Gata5-Cre. 
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Materials and Methods 
LacZ staining 
Staining for β-galactosidase was performed as described (Soriano, 1999).  
Histology 
Paraffin sections (5µm) were stained with hematoxilin and eosin (H&E) for 
general visualization. Myocardial area was calculated with the contouring tool using 
Canvas X software. Area of the heart was defined as the measure of total muscle 
including both chambers in one whole mount picture. Atrial area was not included. In 
Fgfr1 
Wt1-Cre
, Fgfr2 
Wt1-Cre
 and  Fgfr1/2 
Wt1Cre
. Statistical significance was determined 
using the student’s t-test, with n representing number of embryonic hearts examined.  
 
Whole mount immunohistochemistry of pecam 
Tissue is fixed in 4%PFA overnight at 4°C. Tissue is dehydrated in methanol series 
and block from endogenous peroxidase using 4 to1 volumes of methanol to 30% 
hydrogen peroxide for 3h. Tissue is rehydrated in methanol series. Tissue is 
incubated with ProteinaseK 10μg/ml for 30 min at room temperature. Block with 2% 
skim milk, 5% serum, 0.1%BSA, 0.1%triton-x for 2h. Primary (Abcam, ab28364) 
antibody in blocking overnight. Secondary antibody byotinilated. Develop in DAB.  
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Immunofluorescence 
For immunofluorescence, paraffin sections (5μm) were dewaxed, rehydrated, 
incubated in methanol/hydrogen peroxide, antigen unmasked, and blocked in 10% 
goat serum. Antigen unmasking was performed by incubating sections in 1% trypsin 
for 5 min at room temperature or by pressure cooking in citrate buffer for 15 min. 
Primary antibodies used were cytokeratin (Dako, M3515),vimentin (mouse IgM, 
abcam, ab20346),  Wt-1 (mouse IgG1κ, Dakocytomation, M3561), Secondary 
antibodies were incubated for 1hr and visualized with a Zeiss confocal microscope or 
Zeiss apotome microscope.  
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Figure and Figure Legends 
Figure1. 
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Figure 1. 
β-galactosidase staining of control hearts at E13.5. (A-B) Whole mount β-
galactosidase staining for (A) control (Rosa26) and (B) Rosa26;Gata5-Cre at E13.5. 
(A’) Coronal cross section of control without Cre and (B’) coronal section of 
Rosa26;Gata5-Cre. (A’’-B’’) Magnified inset from black squares in (A’-B’). Scale 
bars: (A-B) and (A’-B’) 500μm, (A’’-B’’) 10μm. 
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Figure 2. 
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Figure 2. 
H&E staining. (A) Coronal cross section of control heart stained with 
hematoxylin and eosin at E13.5. (B) Coronal cross section of Fgfr1/r2
Gata5Ccre
 heart 
stained with hematoxylin and eosin at E13.5. Scale bar: 20μm.  
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Figure 3.  
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Figure 3.  
Pecam immunostaining. (A-B) Whole mount Pecam staining of control (A) 
and Fgfr1/r2
Gata5-Cre
 (B) at E13.5. (A’-B’) Cross-section of whole mount Pecam 
stained hearts at E13.5 control. (C-D) Pecam staining of control (C) and 
Fgfr1/r2
Gata5-Cre
 (D) at E17.5.  Main coronary vessels are highlighter in gray in (C-
D). (E) Quantification of the area of the heart at E13.5 (controls, n=5, Fgfr1/r2
Gata5-
Cre
, n=4) and E17.5 (controls, n=3, Fgfr1/r2
Gata5-Cre
, n=3). Scale bar (A-B) and (C-D) 
500μm, (A’-B’) 20 μm. 
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Figure 4. 
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Figure 4.  
  Immunofluorescence of cytokeratine and vimentin. (A-B) Cytokeratin (red) 
staining in controls (A) and Fgfr1/r2
Gata5-Cre (B). (A’-B’’) Vimentin (green) staining 
in controls (A’) and Fgfr1/r2Gata5-Cre (B’). (A’’-B’’) Merge with DAPI (blue) staining 
in controls (A’’) and Fgfr1/r2Gata5-Cre (B’’). (C) Quantification of cytokeratin average 
fluorescence controls, n=9,  Fgfr1/r2
Gata5-Cre, n=6. Dapi (blue). Scale bar: 20μm. 
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Figure 5. 
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Figure 5. 
Wt1 immunofluorescence. (A-B) Wt1 (red) immunostaining for control (A, 
n=9) and Fgfr1/r2
Gata5-Cre
 (B, n=5). White dashed line delimits the boundary between 
epicardium and myocardium. (C) Quantification of total Wt1 in epicardium (epi), 
subepicardium (subepi), and myocardium (myo) of control and Fgfr1/r2
Gata5-Cre
 at 
E13.5. DAPI (blue). Scale bar: (A-B) 20μm. 
 
 
 
 
 
 
 
 
 
